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Acrolein, a very reactive aldehyde, is a culprit in the biochemical cascade after primary, 
mechanical spinal cord injury (SCI), which leads to the destruction of tissue initially 
unharmed, referred to as “secondary injury”. Additionally, in models of multiple sclerosis 
(MS) and some clinical research, acrolein levels are significantly increased. This 
aldehyde overwhelms the natural anti-oxidant system, reacts freely with proteins, and 
releases during lipid peroxidation (LPO), effectively regenerating its self. Due to its 
ability to make more copies of itself in the presence of tissue via lipid peroxidation, 
researchers believe that acrolein plays a role in the increased destruction of the central 
nervous system in both SCI and MS. Hydralazine, an FDA-approved hypertension drug, 
has been shown to scavenge acrolein, but its side effects and short half life at the 
appropriate dose for acrolein scavenging must be improved for beneficial clinical 
translation. Due to the inefficient delivery of therapeutic drugs, nanoparticles have 
become a major field of exploration for medical applications. Based on their material 
properties, they can help treat disease by delivering drugs to specific tissues, enhancing 
detection methods, or a mixture of both. Nanoparticles made from silica provide distinct 
advantages. They form porous networks that can carry therapeutic molecules throughout 
xvi 
 
the body. Therefore, a nanomedical approach has been designed using silica 
nanoparticles as a porous delivery vehicle hydralazine. The silica nanoparticles are 
formed in a one-step method that incorporates poly(ethylene) glycol (PEG), a stealth 
molecule, directly onto the nanoparticles. As an additional avenue for study, a natural 
product in green tea, epigallocatechin gallate (EGCG), has been explored for its ability to 
react with acrolein, disabling its reactive capabilities. Upon demonstration of attenuating 
acrolein, EGCG's delivery may also be improved using the nanomedical approach. The 
nanoparticles' physical characteristics were characterized and their interactions in vitro 





SCI results in concentrated cell death and leads to a feed forward process of oxidative 
stress that affects healthy tissues around the injury site. The current therapies for SCI fail 
to address the many issues and biochemical events that occur both during and following 
initial injury. Some of the therapies address the initial injury while others help to alleviate 
effects of secondary injury. Therefore, a new therapeutic system is essential to move 
forward in alleviating the disabling effects of SCI. An effective therapy for SCI would 
possess the following characteristics: 
 
 It must have an anti-oxidant property to alleviate the stress on the natural 
glutathione system and address the oxidative stress in secondary injury. 
 It must help to reduce membrane damage in injured neurons to help restore their 
ability to conduct action potentials. 
 It must improve upon current therapies in not only therapeutic value but side 
effects must also be reduced. 
 It must be deemed safe and nontoxic at therapeutically-relevant levels. 
 
Nanomedicine has the advantage over conventional medicine in that it has the potential to 
address many problems in one therapeutic vehicle without prescribing a large, eclectic 
cocktail of therapeutic drugs. The creation of a nanomedical system using silica 
nanoparticles will help to alleviate effects of acrolein after SCI. Prolonging the 
circulation time with mesoporous silica nanoparticles loaded with hydralazine would 
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decrease the necessary dose and increase its chance of reaching the injury site. In using a 
nanomedical approach, the following criteria must be met: 
 
 Cost-effective, reproducible synthesis of nanoparticles with similar qualities and 
characteristics. 
 The nanomedical system must effectively deliver the therapy of interest via 
targeting or a similar mechanism. 
 It must be biologically stable, compatible, and of low toxicity. 
 
  
Therefore, a therapy that addresses these points has potential to transform and expand the 
current knowledge of the field. A system such as this also has direct clinical translation. 
Particularly, hydralazine has already undergone FDA approval. Upon demonstrating the 
safety and efficacy of the delivery vehicle, the nanomedicine has a chance to make its 
way into an approved, effective therapy. 
 
1.2 Specific aims 
Aim I: Design, synthesize, and characterize hybrid silica nanoparticles. There are 
various ways to create silica nanoparticles. A rather simple synthesis that eliminates the 
need to graft or add PEG in a later step involves the co-condensation of PEG with the 
starting siloxane, which has been demonstrated.[1, 2] Both groups also published the 
chemical spectra of the nanoparticles, which can be confirmed upon synthesizing the 





Aim II: Evaluate the toxicity of nanoparticles in vitro. For in vitro studies, the 
nanoparticles would have to show low toxicity to cells. Population-based assays that 
monitor cell activity are commonly used to determine cytotoxicity, but they should be 
corroborated with analysis methods such as cytometry that analyze the characteristics of 
an individual cell. Particularly for looking at cell uptake, toxic effects may differ between 
cells that are merely exposed to nanoparticles and those that internalize the nanoparticles. 
 
Aim III: Explore natural products as potential acrolein scavengers. Although 
hydralazine has been shown to attenuate acrolein, other scavengers may prove more 
effective. An additional aim of this project is to explore the use of a natural product found 
in green tea, epigallocatechin gallate (EGCG), for its potential as a potent antioxidant. 
 
Aim IV: Explore therapy-nanoparticle interactions in a cell-free system. The 
behavior of the nanoparticle-drug complex will behave differently than the nanoparticles 
or therapeutic alone. This aim will achieve to define how the nanoparticles react with free 
therapeutics in a solution-based system.
 
Aim V: Evaluate the efficacy of nanoparticles in vitro. Ultimately, the goal of the 
nanomedical system is to improve therapeutic delivery through prolonged activity or 
reduced degradation of the therapeutic product. This aim is to evaluate whether the 




2.1 Neurological disease 
Neurological injury often results from biological damage, such as multiple sclerosis 
(MS), or mechanical damage, such as compression in spinal cord injury (SCI). 
Regardless of the affliction, a patient’s quality of life is likely reduced due to the loss of 
motor, sensory, or cortical function. Based on epidemiological studies, MS affects many 
more women than men and Caucasian women are more likely to have the disease than 
women of other races.[3, 4] In MS, the body attacks two proteins that hold the protective, 
neuronal myelin sheaths together: myelin basic protein (MBP) and myelin 
oligodendrocyte glycoprotein (MOG).[5] The MBP amino acid composition was fully 
sequenced in the early 1970’s, after much work had already been established regarding its 
role in the nervous system. The sequence supported indications of the protein’s function 
and location within the myelin.[6] Alternatively, MOG, the other major myelin protein, 
has a large, open active site that antibodies easily tag for attack in MS patients.[5] The 
cause for the sudden attack is still unclear, but research continues to explore both 
biological and environmental factors.[7, 8, 9] 
 
SCI and traumatic brain injury (TBI) are traumas to the central nervous system (CNS). 
Motor vehicle accidents most heavily contribute to the occurrence of CNS injuries. Since 
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young adults and teens are most likely to be involved in these types of accidents, their 
age group is significantly affected.[10] Aside from possible mortality, injury usually 
results in impaired motor capabilities (paralysis), sensory capabilities (hypersensitivity 
and hyposensitivity), and/or neurologically-based pain. This can drastically reduce a 
patient’s quality of life and place a large burden on society, both in health care costs and 
lost productivity. Regardless of how the CNS is damaged, it has adverse effects on a 
patient. The origin of these three neurodegenerative disorders is summarized in Table 2.1. 
Although not ideal, therapies have been developed for the different conditions, but 
discussed later, the treatments may have little effect or adverse side effects, which calls 
for a new approach to treating disease. 
 
Table 2.1. Summary of MS and SCI/TBI 
 MS SCI/TBI 
Origin 
Auto-immune response to 
myelin-associated proteins in 
spinal cord 
Mechanical or chemical 
damage to brain or spinal cord 
Symptoms 
Lesions of the brain and 





Some linked genetic and 
environmental risks 





Most common in Caucasian 
women 
Occurs more frequently in 












2.2 Nanotechnology: A new medical approach 
Nanotechnology holds promise in aiding to treat chronic disease and medical conditions. 
In biology and medicine, the field has developed rapidly in the last decade to create a 
new segment of nanotechnology: nanomedicine. Major goals of the field involve the 
improvement of drug delivery, diagnostic or imaging techniques, and theranosis, which is 
a combination of both. It gives rise to therapies that can be tailored to diagnose and treat 
for specific disease states while diminishing the side effects of traditional medicine. 
Additionally, as the field broadens, it expands to include nanopharmacology and 




Figure 2.1. Representation of a nanomedical system adapted from Prow et al.[16] 
 
The composition of nanoparticles is extremely diverse. They have been synthesized using 
a wide range of materials: metal (e.g. gold, silver, cadmium), metal oxides (iron oxide, 
titanium oxide, zinc oxide), silica, polymers, biological molecules (peptides and DNA), 
7 
 
among others.[17, 18, 19, 20] As the field has progressed, more nanoparticles are being 
made from mixtures of these materials, which provide new benefits and functions for the 
various applications that a single material will not possess. Many times, the 
amalgamation allows both the diagnostic and therapeutic effects to occur either 
simultaneously or in a time-dependent manner. This is achieved by making nanoparticles 
one a layer at a time, called layer-by-layer synthesis. Each layer changes a nanoparticle's 
characteristics and adds functionality, essentially making the nanoparticle programmable. 
The multi-functional nanoparticles become a unique nanomedical system used to address 
a biological problem. An example is shown in Figure 2.1. 
 
2.3 Neurological disease pathology: Overview 
2.3.1 Neurological degeneration in spinal cord injury 
Although it can recover somewhat, generally, the CNS recovers very little after injury. 
On the other hand, the peripheral nervous system (PNS) recovers more efficiently. The 
enzymatic and molecular composition of the neurons contributes heavily to the 
differences in their regeneration. The CNS myelin, composed of oligodendrocytes, 
contains direct inhibitors of axonal growth, such as the aptly-named Nogo receptor, that 
interact with myelin proteins.[21, 22, 23, 24, 25] In the PNS, protective Schwann cells 
form a scaffold that allows the renewed growth of injured axons.[26, 27, 28] Injury to the 
CNS also affects a patient more critically. The brain and spinal cord are the control 
centers for the body's many functions. When messages cannot be transported back and 
forth, the brain cannot relay appropriate responses to incoming sensory information, or it 
does not receive the information at all. In the PNS, although the loss of information may 
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be detrimental, it is usually both locally concentrated and less critical than the copious 
amounts of information the brain and spinal cord both sends and receives. In the CNS, 
the axons of the neurons can be quite long, and once damaged or destroyed, the 
information from a large part of the body is lost. 
 
In places in and around the injury site, cells often suffer from membrane and myelin 
damage.[15] Neuronal membrane integrity is critical to cellular function. The membrane 
not only retains chemicals and proteins but also prevents them from entering. A neuron’s 
function depends on specific ion concentration gradients between the extracellular and 
intracellular spaces. Extracellularly, sodium and calcium ions are abundant in comparison 
to the cytosol. Intracellularly, the potassium ion concentration is much higher inside the 
cell. In a normal cell, the differences in concentration create a voltage potential across the 
membrane and polarize the cell.[29] When the membrane is compromised, allowing the 
free movement of ions, the gradients diminish or disappear. The cell depolarizes, and the 
leaky membrane prevents it from repolarizing, thereby destroying its ability to generate 
an action potential. Beyond that, other chemicals, such as reactive species and proteins, 
can invade and damage the cell, generating secondary injury and necrosis in a cycle. The 
cycle of stress and death impedes the cells’ abilities to recover from the inundation of 
toxins and return to homeostasis. 
 
In the CNS, oligodendrocytes are responsible for myelinating neuronal axons. The 
oligodendrocytes form segments of sheaths around the axons. The spaces between the 
segments are called the nodes of Ranvier. The sheaths allow action potentials to “jump” 
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quickly from node to node.[29] Furthermore, the junctions contain distinct enzymes and 
signaling molecules to keep different ion channels segregated. The nodes of Ranvier 
contain potassium channels, and the sodium channels congregate in the adjacent 
juxtanodal regions. The channels open and close at different points during an action 
potential, and not only does the separation of the ion channels allow the movement of the 
action potential, but it also facilitates faster depolarization along the axon.[30, 31] When 
the ion channels do not remain separated, neuronal function is impaired.[30] Therefore, 
after demyelination, when the ion channels are desegregated, the neuron’s ability to 
transmit action potentials is hindered or destroyed. Beyond SCI, demyelination is a large 
issue in the progression of other neurodegenerative diseases, such as MS.[5, 32] 
 
At a deeper level, initial SCI results in a concentrated site of necrotic cell death, 
membrane damage, and often, myelin damage. In opposition to apoptosis, where cell 
contents are packaged and recycled before cell death, the contents of necrotic cells are 
released haphazardly into their environment. Normally, the body uses many of the 
molecules that are released during necrosis for various mechanisms, including signaling, 
degradation, and synthesis.[33, 34, 35, 36, 37] Hydrogen peroxide and nitric oxide, both 
potent oxidative species, are secondary messengers for different cellular pathways.[34, 
36] For instance, nitric oxide is a secondary messenger that results in vasodilation of 
smooth muscle, among other functions.[34] To help destroy invading pathogens, 
hydrogen peroxide is secreted by cells responsible for immunity.[35] The superoxide 
anion is produced in the mitochondria during the electron transport chain. The 
combination of superoxide and nitric oxide results in peroxynitrite, and its formation and 
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sequestration by uric acid after SCI was studied and found to ameliorate some effects of 
peroxynitrite formation, but the major mechanism seemed to stem from attenuating the 
inflammatory response from immune cells.[38] Vitamin B12 works specifically through a 
radical reaction with cobalt, creating upstream products for DNA synthesis.[33] Upon the 
uncontrolled release, though, many of these molecules and enzymes, specifically reactive 
oxygen species (ROS) and reactive nitrogen species (RNS) (Figure 2.2), travel to 
neighboring cells, including healthy ones, and cause secondary damage through effects 




Figure 2.2. Common ROS and RNS. The formation of such species is normally highly 
controlled for specific signaling mechanisms (nitric oxide), respiration (superoxide), or 
defense (hydrogen peroxide). When cells are damaged, radicals can freely form and 
travel to uninjured, healthy cells. Environmental factors may also contribute to the 
formation of oxidative stress. Therefore, reducing oxidative stress is a critical field for 
nanomedicine to address. 
 
2.3.2 Biochemical targets of  SCI 
In both SCI and MS, inflammation plays a role in the health and progression of the CNS 
neurons. In vitro, activated microglial cells induce oxidative stress when cultured with 
neuronal cells.[41, 42] Although the response is natural, the oxidative stress can be 














attacks its own cells, such as in MS, the sites are pervasive rather concentrated. Figure 




Figure 2.3. Progression of primary injury and secondary injury. After primary injury, the 
biochemical cascade that follows is secondary injury. The secondary injury can cause 
damage to tissue that was previously unharmed, perpetuating a cycle of oxidative stress 
and injury. 
 
Acrolein (Figure 2.4), a reactive oxygen species, has been implicated in secondary injury 
in neuronal tissues.[43, 44] Both studies found increased LPO specifically caused by 
acrolein. Luo et al. monitored acrolein's protein adducts after spinal cord injury in vivo. 
They found that acrolein levels peaked 24 hours after injury, but stayed elevated for up to 
a week.[44]  Later studies explored the various biochemical changes caused by acrolein 
in neuronal tissues, including LPO, myelin damage, and mitochondrial damage.[45, 46, 
Necrosis releases cellular contents (primary)
Inflammation and ROS/Acrolein
Lipid peroxidation
Membrane and myelin damage
Loss of function and homeostasis
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47] Acrolein's primary carbon can undergo nucleophilic (nucleus-loving) attack, but 
contributing to its destructive nature, the electrophilic (electron-loving or electron 
deficient) carbons of the π-bond (second bond of C=C) can undergo attack by 
nucleophiles in the cell. Specifically, acrolein reacts with amine-containing lysine 
residues, histidines, and electrophilic unsaturated fatty acids. When acrolein attacks fatty 
acids, more is generated in a cycle of uncontrolled LPO.[48] Environmentally, it is a by-
product in the burning of plastics, overheated cooking oil, and cigarette smoke, which 
makes it an important environmental source of oxidative stress that can adversely affect 




Figure 2.4. Acrolein is a reactive oxygen species implicated in secondary injury after 
SCI. The pi-bond reacts with proteins and lipids, altering the function of proteins or 
causing lipid peroxidation. The carbonyl of acrolein is still free for other reactions, such 
as those used for scavenging. 
 
When acrolein reacts with lipids, such as those in the cell membrane, the membrane is 
compromised, and more acrolein is released to attack other tissue in a feed forward 
process (Figure 2.5). It creates a cascade of oxidative stress to a particular area of injury. 
In this way, acrolein can increase the stress and damage healthy tissues surrounding the 
injury site.[39, 45, 52] The large amount of oxidative stress overwhelms the body's 
natural anti-oxidant, glutathione.[53] Normally, glutathione is oxidized, which stops ROS 





its original form by glutathione reductase. In a large area of oxidation, glutathione cannot 
be reduced quickly enough to account for the overwhelming, cyclic, and unchecked 
production of acrolein. Furthermore, the protein adducts of acrolein cause functional and 
conformational changes in the proteins and is hypothesized to contribute to the plaques 




Figure 2.5. Representation of secondary injury caused by acrolein travelling from a 
primary injury site to healthy tissue. 
 
Although other biological factors may play a role in spinal cord injury, such as various 
molecular pathways, inflammation and acrolein are two targets that current therapy 
(discussed in the next section) does not sufficiently address. Particularly, acrolein's 
persistence in vivo leads to more oxidative stress that can travel to healthy tissues, 
causing the injury site to grow beyond the initial trauma point. Furthermore, unlike other 
oxidative species, its levels remain high, which hinders the tissues' abilities to recover 
effectively. Specifically, both acrolein and inflammation can lead to necrosis, which 
negatively impacts not only the dying tissue, but also the surrounding tissue. In a 
sensitive area like the spinal cord, necrosis and damage can affect the entire body, not 
just a concentrated area. 
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2.4 Therapeutic explorations in treating spinal cord injury 
2.4.1 Immunosuppressant 
Although methylprednisolone, a steroid, is the most common drug used for spinal cord 
injury, it has received criticism.[55] Hugenholtz et al. concluded that the drug is too 
expensive to prescribe with the current clinical data that is scattered and 
inconclusive.[55] Bracken et al. recommend that the drug be given within the first eight 
hours post-injury to be effective.[14] Regardless, the drug aims to suppress the immune 
system, reducing inflammation around the injury site. Although it may attenuate 
oxidative stress and cytokines from immune cells, it does not address the process of stress 
from the dead or dying cells. Therefore, more work needs to be done to find new and 
more effective therapies for spinal cord injury. 
 
2.4.2 Glutathione 
A seemingly easy approach for improving the body's stores of antioxidants includes 
glutathione supplementation (Figure 2.6). The molecule is made from cysteine, glycine, 
and glutamate, and its anti-oxidant properties stem from the nucleophilic thiol group of 
the cysteine. Oxidative species are electrophilic, and the extra valence electrons of the 
thiol group reduce the oxidative species and create water in the process. In other words, 
the anti-oxidant is oxidized rather than allowing essential parts of the cell from being 
oxidized. Unfortunately, orally-administered glutathione itself is poorly absorbed.[56] 
Studies of glutathione levels found that it forms an equilibrium with its amino acid 
components through synthesis of glutathione and uptake of cysteine.[57, 58] Therefore, 
to increase glutathione levels, rather than absorbing glutathione, increasing the uptake of 
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its amino acid components shifts the equilibrium towards synthesis of glutathione, which 




Figure 2.6. Glutathione. The thiol (-SH) group contributes to its anti-oxidative properties. 
The body naturally controls the production and reduction of glutathione from its oxidized 
state. In cases of severe oxidative stress, the reduction occurs too slowly for cells to 
overcome the assault of ROS or RNS. 
 
2.4.3 Hydralazine as an acrolein scavenger 
Fortunately, the drug hydralazine (Figure 2.7), which is commonly used to treat 
hypertension, has been found to “scavenge” for acrolein and other oxidative species.[8, 
39, 45, 59, 60, 61] Particularly, the drug will scavenge and react with acrolein that has 
reacted with proteins.[45] As mentioned earlier, the carbonyl group in acrolein is free for 
nucleophilic attack. Once acrolein reacts with a protein, the carbonyl is free, and 
hydralazine can attack it. The reaction results in a Schiff-base, imine (C=N bond) 
formation, which the body uses regularly for amino acid synthesis (Figure 2.8). When the 
drug reacts with free acrolein, it reduces the amount of acrolein that can induce LPO, 
arresting the feed forward production of acrolein. Ultimately, stopping the process would 















Figure 2.7. Hydralazine (left) and the imine product of acrolein and hydralazine (right). 
The Schiff base on the right is the product of hydralazine scavenging acrolein and likely 
to occur in a cellular environment, as similar reactions are used for amino acid synthesis. 
If acrolein has already reacted with proteins, hydralazine can still react with acrolein for 
removal. 
 
Currently, hydralazine is used for hypertension. It activates a G-protein coupled receptor, 
guanylate cyclase, in smooth muscle, causing a downstream signal to relax the smooth 
muscle.[62] Due to this mechanism, administering hydralazine for acrolein scavenging 
could critically lower an injured patient’s blood pressure. Furthermore, hydralazine has a 
fairly short half-life of about 2 h in vivo, and genetic factors influence the metabolism and 
side effects of the drug. Some patients who metabolize the compound quickly have been 
shown to exhibit lupus-like symptoms.[63] Therefore, a therapy that could locally 
concentrate hydralazine without lowering blood pressure and invading other tissues 
would have great potential for SCI patients. 
 
2.4.4 Polymeric, therapeutic molecules 
Long-chain polymers have also been studied in SCI. Poly(ethylene) glycol (PEG) and 
chitosan have both been studied for their effects on treating the effects of SCI and other 
neurological diseases.[8, 52, 61, 64] The polymers first plug the damaged membrane by 
associating with the holes. The interaction of the polymers then causes the two separated 
17 
 
parts of the membrane to associate with each other, effectively closing the hole and 
stopping the invasion of unwanted ions and molecules.[52, 64] 
 
The two polymers have a few distinct differences. The molecular weight of PEG ranges 
from very small (MW 250) to very large (MW 500K), depending on the application. It 
also comes with a range of functional groups for different modifications or can be 
modified for functionality. The applications and functionalities of PEG will be discussed 
in the next section. Chitosan, on the other hand, is derived from the exoskeletons of shell 
fish such as crabs and shrimp.[65] Chitin, the polymeric material from the shells, is 
deacetylated in various degrees to create chitosan. Chitosan alone is not water-soluble; 
therefore, it must be modified to make it water-soluble.[19] The properties of 
PEG/chitosan blends have also been studied to combine the biodegradation and 
biocompatibility effects of both polymers.[66, 67, 68] De Campos et al. compared 
polymeric particles coated with PEG and those coated with chitosan for therapeutic 
delivery to the cornea. They found that PEG had better delivery, but chitosan had a better 
drug retention effect.[69] 
 
2.4.5 Treatment Summary 
A number of different molecules have been used to target the symptoms of SCI. All of 
them attempt to address some, although not all, characteristic of SCI. Table 2.2 
summarizes the origin and action of many of the common therapies. Table 2.3 shows the 
different side effects that each therapy addresses. It is evident that a new approach is 
necessary to address the complex processes that occur during and SCI. 
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Table 2.3. Therapeutic value of SCI therapies 
 Aids membrane repair Anti-oxidant 
Glutathione No Yes 
Methylprednisolone No No 
Hydralazine No Yes 
Poly(ethylene) glycol Yes No 
Chitosan Yes No 
 
Since the major explorations involve controlling one of the aforementioned aspects of 
SCI, a therapy that could combat all of them would be a large step in helping SCI 
patients. Granted, axonal regeneration is an additional factor after SCI, but oxidative 
stress leads to apoptosis and necrosis. Controlling and preventing cell death is extremely 
important before tissues can repair themselves. Additionally, a major problem in 
inflammation is the induction of oxidative stress through cytokines. Rather than affecting 
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a patient's entire immune system, it is more beneficial to locally control the inflammatory 
and oxidative stress through a small scavenger like hydralazine. Decidedly, though, when 
used singly, the current therapeutic approaches have limited efficiency and usage. 




Due to current therapeutic limitations, a nanomedical approach may help to ameliorate 
poor drug availability and the biochemical effects of secondary injury. In current 
therapies, drugs are administered and, hopefully, arrive at their intended location by 
random chance. Nanoparticles can act as carriers and increase a therapy's circulation 
time, which is critical for hydrophobic and short-lived therapies, thereby improving the 
therapy's chance of reaching the cells of interest. Furthermore, biomolecules (natural or 
mimetic) can be added to the nanoparticle assemblies to help with cell-uptake specificity. 
After circulation and accumulation, the biomolecule hopefully increases the likelihood of 
nanoparticles being internalized by the intended cells.[74] Peptides, DNA, RNA, and 
receptor ligands have been used for their affinity for a particular biomarker or 
characteristic, such as an increase in folate receptors on cancer cells.[75, 76, 77, 78, 79] 
Unfortunately, the disease state must have a studied, reliable biomarker to target, which 
may not always be the case. Without these moieties, nanoparticles may accumulate in 
different areas by changing their shape or size, for instance.[80, 81] Different clearance 
organs, such as the spleen, liver, and kidneys, will filter out particles based on their size. 
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He et al. specifically found that smaller particles (< 200 nm) were less likely to 
accumulate in the spleen and liver compared to the larger particles.[80] 
 
Table 2.4 summarizes many of the common materials used to make nanoparticles. The 
list includes inorganic material (silica and iron oxide), transition metals (gold and 
quantum dots), and organic materials (chitosan, DNA, PEG). Each material harbors 
certain advantages and disadvantages versus the others. Efforts have also explored hybrid 




























































































































































































































































































































































































































































































































































































































































































































































Table 2.4 indicates that both silica and polymeric NPs provide essential features to 
ameliorate the limitations of current SCI therapies, most notably their ability to adsorb 
and encapsulate drugs. The distinct, overwhelming advantage silica nanoparticles provide 
is the ability to form a mesoporous network. The porosity makes them especially useful 
for various medical applications that include drug and gene delivery.[60, 110, 111, 112, 
113] Particularly, the tunable mesoporous structure of silica networks give them qualities 
of zero-order drug release.[114] The drug is released at a constant, rather than 
exponential or logarithmic, rate, which could prevent side effects from high drug doses 
and lower the amount of drug necessary for effective delivery. The silica encapsulates the 
drug until reaching the cell or cells of interest. The method can be applied to potent 
drugs, such as chemotherapy agents or environmentally-sensitive drugs. 
 
In polymeric nanoparticles, the drugs are usually encapsulated via self-assembly.[98] 
Polymeric nanoparticles are usually created via sonication or mixing that causes them to 
assemble into nanostructures.[17, 115] When the nanoparticles disassemble in biological 
systems, the drugs are released in a burst, which is usually the cause of adverse side 
effects.[99] When therapies are released rapidly, a high local concentration can be toxic 
to cells, especially in the delivery of very potent drugs (chemotherapy agents). 
Avgoustakis et al. synthesized polymeric nanoparticles and in initial release, about 20% 
of the anti-cancer drug cisplatin was released.[17] Zhang and Feng also had an initial 
burst of the anti-cancer therapy paclitaxel of about 20%.[115] In the other types, the 
therapies are usually added by a type of conjugation method, which can be limiting when 
needing to deliver a small molecule. 
23 
 
Various examples of using silica to deliver therapeutic molecules have been recently 
demonstrated. Chauhan and co-workers have used silica hydrogels to load hydrophobic 
drugs and monitor their release profile from contact lenses for glaucoma. They found 
ways to change the release profile and cause release for weeks or months.[116, 117, 118, 
119] The therapeutic agents can be loaded by incubating them with the porous silica. 
Molecular interactions, generally Van der Waal's forces, cause the drug to adsorb on the 
surface of the silica.[60, 113] Yu et al. successfully coated iron oxide nanoparticles with 
silica for the purpose of protein adsorption.[103] 
 
Silica nanoparticles can be prepared and functionalized in various ways. The starting 
material, or precursor, is generally a small siloxane, such as tetramethylsiloxane (TMOS) 
or tetraethylsiloxane (TEOS). Upon addition of acid or base, the precursor hydrolyzes 
and eventually condenses to form the silica network at room temperature (Figure 2.8). 
Although many reaction types exist, many of these stem from the Stöber method that was 
published in 1968.[85] The method requires the use of a light alcohol (methanol or 
ethanol) and ammonium hydroxide for catalysis.[85] A common variation on this method 
includes the water-in-oil microemulsion, which uses a non-miscible solvent (alkanes) and 
a surfactant.[120] Explorations of other reagents include an array of bases, solvents, and 
even templates for silica nucleation. The templates are usually an organic salt, such as 
cetyltrimethylammonium bromide, that creates a surfactant layer for the nanoparticles to 
form in the two-solvent system. In a later step, though, the template must be removed to 
create the silica shell structure. Because the template is usually a salt, it is removed using 
strongly acidified alcohol, which adds an additional step to the overall synthesis. A 
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similar method for nucleation has been employed to coat iron oxide nanoparticles with 
silica.[20] Depending on the various reaction conditions, the pore size, surface area, size, 
and shape of the nanoparticles will change.[84, 121, 122, 123, 124] Starting material 
concentration, catalyst concentration, and the solvent system also play an important role 




Figure 2.8. Formation of silica network with TMOS precursor. A silica precursor (often 
TMOS or TEOS) undergoes hydrolysis in the presence of an acidic or basic catalyst 
followed by condensation with another hydrolyzed silica precursor molecule. The 
formation and size of size of silica nanoparticles is dependent on precisely controlling the 
rate of both steps. 
 
Different functional groups can be introduced on the surface of the silica by adding an 
additional precursor with a functional group of interest, which is known as the co-
condensation method. Using this method, the functionality and application of silica 
nanoparticles has greatly improved. The organosiloxane is introduced in the original 
mixture or grafted onto the nanoparticles in a later reaction. In grafting reactions, it is 
possible that the functional groups will become part of the silica network or nucleate, 
creating new nanoparticles.[124, 125] Therefore, not only does grafting create a separate 
step in the synthesis of the nanoparticles, but it may also create diverse populations of 
nanoparticles in one mixture. This adds both time and cost to the overall process if the 




















come with a variety of groups, such as carboxylic acids, amines, and polymers, which are 
especially useful for biological tethering. 
 
PEG is a biocompatible polymer that is commonly used for a “stealth” layer on 
nanoparticles.[2, 126, 127, 128, 129] PEG prevents protein adsorption on the surface of 
nanoparticles during circulation (opsonization), which “hides” the nanoparticles from 
attack by immune cells. It can be combined with silica to improve aqueous stability, 
retention, and reduce toxicity both in vivo and in vitro.[1, 127, 129, 130] Similar to other 
reaction conditions, even the amount of PEG seems to affect the size of silica 
nanoparticles.[127] Similar to organosiloxanes, PEG is available in numerous sizes and 
may have a number of functional moieties for various applications. Furthermore, PEG 
provides additional targeting for both localization and therapy for SCI applications. A 
local injection of PEG helped to alleviate systems of oxidative stress in neuronal cells by 
aiding in repairing damage to the membrane.[52] 
 
Cytotoxicity has been a concern with silica nanoparticles, though. Studies with them have 
found that both very small and very large nanoparticles tend to create toxicity problems. 
On the other hand, nanoparticles in the sub-micron range (50-300 nm) exhibit a lower 
toxicity.[82, 83, 131] In in vivo studies, there are mixed results. Table 2.5 shows a few 
highly-cited studies on silica nanoparticle toxicity. For comparison purposes, it only 
highlights single-dose toxicity studies in mice. Hudson and co-workers found their 
nanoparticles to be the most toxic using both intraperitoneal (IP) and intravenous (IV) 
injections. Based on the characterization of their nanoparticles, their results seem to be 
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attributed to the dose and size of their nanoparticles. Although all the studies used both 
dynamic light scattering (DLS) and electron microscopy (EM) to confirm and corroborate 
their size results, Hudson and co-workers had a disparities among the size of 
nanoparticles for each method. 
  
Dynamic light scattering measures the radius a particle appears to have in solution. 
Components of a solvent or buffer form a layer that moves with the nanoparticle, forming 
the hydrodynamic radius. As a particle moves through solution (Brownian motion), it 
scatters light that can be collected. A large particle moves more slowly and scatters less 
light while a smaller particle moves more quickly in comparison.[132] Obviously, since 
the particles are moving in a fluid, the solvent properties, specifically viscosity, changes 
their motion in the fluid system. In EM, the particles are dried and may be sputtered 
before being imaged, which can cause aggregation.[133] Therefore, DLS is likely a truer 
measurement of how the silica nanoparticles behave in a fluid, biological system. Hudson 
et al. had very large particles (470 nm ± 252) based on DLS measurements while SEM 
showed particles of only 100-150 nm. In their preparation for DLS, they described that 
the samples were sonicated and vortexed for two hours prior to the measurement, which 
is a good indication that their particles were probably both large and aggregated if such 
forces were needed to separate them. Furthermore, they mentioned that even after 
preparation, the particles would fall out of suspension.[134] The size of the particles, 
coupled with the large dose, likely contributed to the erratic behavior and mortality of the 
mice. Granted, both Hudson et al. and Liu et al. found that high doses (>1000 mg/kg) of 
the nanoparticles had some toxic effects. 
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Table 2.5. In vivo studies of silica nanoparticle toxicity 
 Type Size (nm) Dose Toxicity 




TEM: 80, 120, 
200, and 360 
DLS: little larger 
20 mg/kg IV 
No toxicity; no 
pathological changes 





TEM: 80, 120, 
200, and 360 
DLS: little larger 
20 mg/kg IV 








30 mg IP  
(1200 mg/kg) 







6 mg IV 






DLS and TEM: 
110 
40, 160, 500, 
1000, and 1280 
mg/kg IV 




2.6 Integrating neurological disease and nanomedicine 
A few efforts have been made to incorporate nanotechnology and SCI. Specifically, Cho 
et al. synthesized silica nanoparticles to deliver hydralazine to healthy cells that had been 
exposed to acrolein.[60] They used a template-based synthesis of their silica 
nanoparticles, grafted an additional silica layer, and attached a PEG layer. In the end, the 
particles were around 126 nm. They were able to deliver hydralazine to PC-12 cells (rat 
neurons) over a period of five days in vitro but not in a linear fashion. The bulk of the 
drug was released in the first few hours. Based on numerous cell assays that measure cell 
viability and therapeutic activity, they concluded that their nanoparticles were able to 
rescue the neurons without inducing further toxicity. In a separate study, they used 
similar nanoparticles ex vivo after crushing the spinal cord.[136] The particles did not 
contain hydralazine for acrolein scavenging and appeared to recover their ability to 
conduct action potentials nearly to the pre-crush level. They speculate that the recovery 
originated from the PEG coating on the outside of the nanoparticles. 
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Later, they attempted to use chitosan-based nanoparticles to study acrolein scavenging. 
Hydralazine was encapsulated by the assembled nanoparticles, which had a diameter of 
around 350 nm. They found that the chitosan nanoparticles had lower encapsulation 
efficiency, but they were still able to decrease the death of healthy cells exposed to 
acrolein.[72] Yet Tysseling-Mattiace et al. used self-assembling peptides to try to 
promote axonal regeneration after SCI. Their mice improved in motor capabilities and 
they found decreased apoptosis in and around the injury site.[137] Again, these 
approaches address some of the SCI problems and show promise of using a nanomedical 
approach, but it can be improved. 
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CHAPTER 3. AIM 1: DESIGN, SYNTHESIZE, AND CHARACTERIZE HYBRID 
SILICA NANOPARTICLES
3.1 Introduction 
There are various ways to create silica nanoparticles.
 
[60, 126, 127, 130, 138]  A rather 
simple synthesis that eliminates the need to graft or add PEG in a later step involves the 
co-condensation of PEG with the starting siloxane, which has been demonstrated.[1, 2] 
The "stealth" polymer, generally designed to prevent the deposit of proteins on its surface 
to minimize interactions with the immune system and increase circulation time, must be 
conjugated to a functional group present in the original nanoparticles or grafted via 
electrostatic interactions. In the former schemes, an additional organosiloxane, generally 
containing an amine or carboxylic acid derivative, is added with the precursor (TMOS or 
TEOS) to functionalize the nanoparticles. The PEG, functionalized with a reactive 
moiety, is then conjugated to the nanoparticles.[126] The PEG content relies on the 
functionalization with the organosiloxane, and depending on whether the organosiloxane 
modification occurs during or after initial particle formation, the synthesis requires two to 
three steps. With PEG grafting, the PEG coats the nanoparticles via electrostatic 
interactions.[130, 138] Over time, the PEG may dissociate from the silica nanoparticles, 
or the coatings may become uneven. In the current study, the PEG serves a dual purpose. 
PEG is nanomedicine's "stealth" molecule, as it has been shown to prevent 
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opsonization.[18, 129] Specifically for spinal cord injury, PEG serves as a target for 
injured neurons and associates with them, aiding in membrane repair.[52] 
 
3.2 Materials and methods 
3.2.1 Synthesis of  mPEG-amine silica nanoparticles 
The silica nanoparticles were synthesized using a modified Stöber method.[2, 85] 20 mg 
of amine- modified methoxy poly(ethylene) glycol (mPEG-Am) MW5000 (0.004 mmol) 
(Sigma, St. Louis) was dissolved in 6 mL of methanol. Upon dissolution, 64 uL of 
tetramethylorthosilicate (0.434 mmol) (TMOS, Sigma, St. Louis) was added. Drop wise, 
750 uL of 2 M NaOH (1.5 mmol) was added to the mixture while agitating. The solution 
was vortexed at 25°C for 1 hour.  To remove  most of the solvent, the milky solution was 
added to a 30 kDa Amicon membrane filter (Millipore, Billerica, MA) and centrifuged 
for 15 minutes at 2800 g. The filtrate was removed, and 5 mL of nanograde water was 
added to the filter and spun again for 10 minutes. The solution was aged for 15 days 
before 3 mL of nanograde water was added to the filter and spun for 15 minutes. Residual 
methanol was removed via evaporation. Concentration of the nanoparticle solution was 
obtained gravimetrically by solvent evaporation under vacuum. For use in cell culture, 
the nanoparticle samples were sterile filtered using a 0.2 µm syringe filter and diluted to 
appropriate concentrations in phosphate buffered saline (PBS). 
 
3.2.2 Synthesis of PEG-hydrazide silica nanoparticles 
Synthesis proceeded as described for mPEG-Am nanoparticles. mPEG-hydrazide 
MW5000 (mPEG-Hz) was obtained from Laysan Bio, LLC (Arab, AL). 
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3.2.3 Size measurements and stability 
The dynamic light scattering (DLS) of nanoparticles was measured in both nano-grade 
water and PBS using a Zetasizer NS (Malvern, United Kingdom) at 25°C and 37°C. Each 
measurement was taken four times to create an average result. The polydispersity index 
(PDI) of the nanoparticles was also determined to avoid conditions where the 
nanoparticles would aggregate. For stability measurements, the samples were stored at 
25°C and measured at various time points. Upon loss of volume, 200 uL of the 
appropriate solvent (water or PBS) was added to the sample before measuring. 
 
3.2.4 Zeta potential 
The interaction of all particles in aqueous media is governed by the “zeta potential” of 
both the cells and the nanoparticles. The nanoparticles were measured in both nano-grade 
water and PBS at pH 7 using a Zetasizer NS (Malvern, UK) at 25°C and 37°C. Each 
measurement was taken three times to create an average result. Since zeta potential 
includes the particle-associated counter-ions attracted to the particle or cell from the 
medium, the zeta potential will be different in water versus PBS. 
 
3.2.5 Fourier Transform Infrared (FTIR) infrared spectroscopy 
As synthesized nanoparticle samples were previously suspended in nano-grade water. 
Amine-terminated methoxy PEG was dissolved in nano-grade water. Ten uL of 
nanoparticle or PEG solution was placed onto a crystal KBr card (International Crystal 
Laboratories, NJ) and allowed to dry. Before running samples, a water background was 
obtained. Each spectra was obtained with 256 scans on a Nicolet FTIR (Thermo 
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Scientific) and processed using KnowItAll Informatics System (Bio-Rad). The FTIR 
spectra were used to examine specific bond arrangements important to the correct overall 
assembly of the nanoparticles and conjugated molecules. 
 
3.2.6 Reflective hyperspectral imaging 
Samples for reflective hyperspectral imaging (RHI) were sent to Cytoviva, Inc in Arab, 
AL. For PEG modification on the nanoparticles, nanoparticles with and without PEG 
were sent for spectral analysis, along with PEG alone. The spectra were compared and 
both silica nanoparticles and PEG were mapped in the PEGylated nanoparticle sample. 
RHI, unlike electron microscopy techniques, can be done on samples in an ambient 
environment rather than dry, vacuum conditions. Samples that are not electron dense can 
also be imaged using this technique. 
 
3.3 Results and discussion 
3.3.1 Synthesis of mPEG-Am nanoparticles 
The silica nanoparticles were prepared to incorporate the polymer into the silica network, 
which eliminates an additional PEGylation step that is common in many other synthesis 
schemes. In the one-step synthesis, the PEGylation is a function of its hydrolysis and 
condensation with the siloxane (Figure 3.1). Furthermore, the Stöber method creates 
water and alcohol as by-products, eliminating the need to remove the organic solvents 
and surfactants in emulsion techniques. Volatile alcohols are fast and easy to remove. 
Inorganic surfactants used to synthesize silica nanoparticles require harsh, acidic 
environments to remove them from the surface of the silica nanoparticles.[121, 133, 139] 
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Ma et al. reported a synthesis technique using a combination of the Stöber and 
emulsification methods.[140] The synthesis and purification was performed at 30°C and 
utilized a surfactant with an alcohol and water solvent system. Especially for use in 
biological systems and scaling procedures, eliminating side products and steps may make 




Figure 3.1. Synthesis scheme of Si-mPEG NP's. The silica precursor, TMOS, is 
hydrolyzed and condensed with methoxy-PEG and TMOS. Condensation with TMOS 
allows the nanoparticle network to grow whereas condensation with mPEG stops the 
growth of the particle. 
 
3.3.2 FTIR analysis of mPEG-Am nanoparticles 
To confirm the synthesis technique, the nanoparticles were analyzed using Fourier 
transform infrared spectroscopy (FTIR). The technique relies on the vibration of chemical 
bonds in a sample using IR. It can be used to compare samples based on the formation or 
disappearance of particular bonds and/or functional groups in the different samples. In 
this study, unmodified nanoparticles and mPEG alone were analyzed and compared to 
mPEG-containing nanoparticles (Figure 3.2). In the plain nanoparticles, silica ester bonds 
are shown the 1300-1000 cm
-1
 region and the same peak appears in the PEGylated 
sample, but it has broadened and contains shoulders from the fingerprint region (900-800 
cm
-1
) of the PEG. Lastly, a weak, broad band has appeared around 2900 cm
-1
 of the 
















Figure 3.2. FTIR spectra of (top left) Non-PEGylated nanoparticles, (top right) mPEG-
amine, and (bottom) mPEG-amine nanoparticles. The bare nanoparticles show 
characteristic peaks of silica-ester bonds in 1200 cm-1 region, which overwhelms the 
smaller peaks of the mPEG-Am alone on the PEG-modified nanoparticles. The 
PEGylated nanoparticles show a slight broadening in the ester region (1300-1000 cm-1), 
which is indicative of Si-O-C bonds after condensation during synthesis. 
 
3.3.3 Reflective hyperspectral imaging of mPEG-amine nanoparticles 
To corroborate the FTIR data, samples were sent to Cytoviva, Inc. for reflective 
hyperspectral imaging. To obtain a spectrum, the technique relies on collecting the 
reflected light from a sample to show spatial co-association of different molecules. For 
the analysis, PEG and nanoparticles with and without PEG were analyzed (Figure 3.3). 
From there, the PEGylated sample was analyzed and using the control spectrum, 
"mapped" for the presence of PEG and silica nanoparticles (Figure 3.4). The PEGylated 
sample shows the presence of PEG and silica juxtaposed. The spectrum of each sample is 
also different. In the PEGylated sample, the spectrum has shifted towards the peak of the 
PEG sample, indicating a change in the reflectance pattern of the sample that could be 

















Figure 3.3.  Hyperspectral maps of mPEG alone (left), non-PEGylated sample (right) and 
Si-mPEG sample (middle). The PEGylated sample shows a shift towards the mPEG 






Figure 3.4. Mapping of mPEG and silica nanoparticles on a pixel by pixel basis. The 
presence of PEG was confirmed after the synthesis of the nanoparticles. Images provided 
by Cytoviva, Inc. (Arab, AL). 
 
3.3.4 Characterization of mPEG-Am nanoparticles 
The synthesized nanoparticles were collected and measured using dynamic light 
scattering (DLS). Specifically for nano-type applications, size, stability, and zeta 
potential are all important characteristics. Therefore, determining these characteristics are 
important if the nanoparticles are to be used clinically. For instance, the body has natural 
size and charge (zeta potential)  filters, including the kidneys, liver, and spleen. Each of 
these organs will remove particles of various sizes and charges, and in order for the 
nanoparticles to be effective, they should be tailored to fall within a range that avoids 




Dynamic light scattering (DLS) measures the radius a particle appears to have in solution. 
Components of a solvent or buffer form a layer that moves with the nanoparticle, forming 
the “hydrodynamic radius”. As a particle moves through solution (Brownian motion), it 
scatters light that can be collected. A large particle moves more slowly and scatters less 
light while a smaller particle moves more quickly in comparison. Based on DLS 
measurements, the nanoparticles have an average hydrodynamic diameter of 21.33 nm 
and a polydispersity index (PDI) of 0.085, indicating a small range of sizes in the 
population (Figure 3.5). The PDI gives an indication of a sample's population 
distribution, ranging from 0.00-1.00. A high PDI usually indicates various size 
populations in one sample. The samples were stored at room temperature in the sample 
cuvette and measured over time. Even after long periods of time, the nanoparticles retain 
their integrity. They can also be diluted into PBS and retain their integrity, but they begin 









Figure 3.5. DLS size of mPEG-Am NP's in aqueous solution after synthesis and after 42 
weeks (10 months) of shelf storage. The sample was pulled directly after synthesis and 
filtered through a 0.2 um. Subsequent measurements were taken of the same sample over 
time. 
 
Directly after removing the organic solvent, the pH of the nanoparticle solutions is about 
10 from the base catalyst. The nanoparticles are stable in the solution, but for biological 
purposes, the pH must be adjusted. To account for this change, the particle solutions were 
diluted, pH-adjusted, and their properties were measured at a neutral pH in both water 
and PBS. 
 
Zeta potential deals with how the nanoparticles arrange charges in a solution, which can 
affect how the nanoparticles will interact with cells. It may affect the pathway the 
nanoparticles undergo. On the other hand, they could either stick heavily to the cell 
membrane or be repelled by the charge arrangements. Zeta potential also gives an 
indication of how the nanoparticles interact with each other. A neutral, or zero, zeta 
potential indicates instability and association of the nanoparticles with each other, which 
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usually leads to aggregation –something highly undesirable, especially in clinical 
applications. 
 






PDI Zeta Potential 




25 Water 24.78 0.147 -29.2 (1.7) -31.7 (6.9) 
25 PBS 24.19 0.121 -25.0 (2.3) -25.4 (1.2) 
37 Water 24.07 0.131 -26.2 (1.1) -29.3 (0.7) 
37 PBS 23.28 0.129 -21.9 (0.8) -23.4 (0.8) 
 
The PDI increases once the pH has been adjusted, which is likely due to a change in both 
the ionic strength and pH (Table 3.1). In more acidic conditions, the positively charged 
hydrogen ions are attracted to the negatively charged surface of the nanoparticle 
becoming part of the associated counter-ion cloud and slightly lowering the zeta 
negativity of the zeta potential. The zeta potential is negative, likely due to the various 
silanol groups on the surface of the nanoparticle. To prevent non-specific sticking of the 
nanoparticles to the cells, which are almost always negatively charged with a zeta 
potential of approximately 10-20 mV, the nanoparticles should be at least slightly 
negatively charged zeta potential of about -5 to -10 mV,  Targeting molecules, in this 
case the attraction of PEG for cell membrane lipids, will overcome a slight electrostatic 
barrier between the nanoparticles and the cells to produce a good targeting effect to 
injured cells. The PEG creates a shielding effect, which changes with the temperature and 
ionic strength. For instance, polymer interactions often change with temperature, and 
those changes are mostly absent in the non-PEGylated sample. The effect of the solution 
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is seen less at room temperature, but at body temperature, the zeta potential increases in 
both water and PBS, which may be accounted for in the ion concentration difference 
between water and PBS. PBS contains more ions to create a plane around the 
nanoparticles, offsetting the high negative charge. The PEGylated sample also has a low 
ratio of amine groups that can contribute to changing the charge around the particle, 
which is not present in the non-PEGylated sample. 
 
3.3.5 Characterization of mPEG-Hz nanoparticles 
The hydrazide nanoparticles have a particular advantage not present with the amine-
modified nanoparticles. The active group of hydralazine is an azine, or R-NH-NH2 off an 
aromatic phthalazine, and its hypertension activity stems from the phthalazine. The 
mPEG-hydrazide contains a similar group, but the aromatic part has been replaced by 
PEG and a carbonyl (C=O) in the R position of R-NH-NH2. This may help the reactivity 
of the azine, as the carbonyl withdraws electrons from the azine, making it more 
nucleophilic. Because its reactivity is higher than that of amine groups, hydrazides are 
often used for bioconjugations. Therefore, the hydrazide group on the end of the mPEG 
may actively scavenge acrolein without the need for drug loading and possible side 
effects from using hydralazine. 
 
Similar to the amine-modified nanoparticles, after synthesis, the hydrazide-modified 
nanoparticles were measured using dynamic light scattering (Figure 3.6). The 
nanoparticles have an average initial size of 20.26 nm in diameter with a PDI of 0.071. 





Figure 3.6. DLS size of mPEG-Hz NP's both after synthesis and 30 weeks (6.5 months) 
of storage at room temperature. The nanoparticles have a narrow size distribution and 
retain their integrity over time. 
 
Similar to the mPEG-Am nanoparticles, the mPEG-Hz nanoparticles remain stable for 
long periods of time in the basic pH, but their size and zeta potential were measured in 
water and PBS at pH 7 (Table 3.2). The hydrazide-modified nanoparticles have a higher 
zeta potential than their amine-modified counterparts, more than likely due to the 
increased amine groups on the end of the hydrazide PEG. 
 





PDI Zeta Potential (mV)  
(St.Dev) 
Zeta of Non-PEG 
sample (mV) 
25 Water 23.00 0.128 -29.5 (4.8) -31.7 (6.9) 
25 PBS 28.33 0.281 -22.2 (2.0) -25.4 (1.2) 
37 Water 22.49 0.149 -22.3 (2.4) -29.3 (0.7) 






3.4 Concluding summary 
This particular aim of the project focuses on the synthesis and characterization of the 
silica-based nanoparticles. This work demonstrates the feasibility of producing 
silica/polymer nanoparticles with a narrow size distribution using a facile synthesis 





CHAPTER 4. AIM II: EVALUATE THE TOXICITY OF HYBRID NANOPARTICLES 
IN VITRO.
4.1 Introduction 
In order for nanomedicine to be clinically relevant, it is imperative that the nanoparticles 
themselves do not induce stress or harm to healthy or injured cells. The nanoparticles 
may induce damage through various pathways. They may cause oxidative stress, 
necrosis, or induce apoptosis, which are important to distinguish. 
 
4.2 Materials and methods 
4.2.1 B35 rat neuroblastoma cell culture 
B35 rat neuroblastoma cells were obtained from ATCC (American Tissue Culture 
Collection) and cultured in T-25 or T-75 flasks with DMEM (Sigma) supplemented with 
10% FBS (Invitrogen). The cells were co-cultured twice per week and were seeded in 
concentrations from 1:4 to 1:8. For all experiments, cells were used in the  log phase of 
growth. 
 
4.2.2 C8-B4 mouse glioblastoma cell culture 
C8-B4 mouse glioblastoma cells were obtained from ATCC (American Tissue Culture 
Collection) and cultured in T-25 with DMEM (ATCC) supplemented with 10% FBS 
(Invitrogen). The cells were co-cultured upon at least 80% confluency (7-14 days) and 
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seeded at concentrations no less than 1x10
5
 cells/mL. For all experiments, cells were used 
in the log phase of growth. 
 
4.2.3 Lactate dehydrogenase (LDH) assay for nanoparticle toxicity 
LDH activity gives a measure of cell's membrane integrity. As the membrane is damaged, 
cytosolic LDH is released from the cell. The LDH Toxicology Kit was purchased from 
Sigma and used per the manufacturer's instructions. B35 cells were seeded in triplicates 
at 5 x 10
5
 cells/mL in DMEM with 10% FBS overnight. The cells were incubated with 
nanoparticles in complete growth medium for 24 hours before analyzing the growth 
medium for LDH activity. To determine the total LDH amount, a set of untreated cells 
were lysed using 0.5% Triton-X. The LDH activity was measured using a VersaMax 
microplate reader (Molecular Devices, LLC, Sunnyvale, CA). The data is reported as a 
change of LDH activity compared to the lysed control wells, calculated as follows: 
 
                     
                                      
                       
     
 
4.2.4 Oxidative stress analysis by LEAP 
Dihydroethidium is a compound that, once activated by reactive oxygen species, 
integrates with DNA and fluoresces red. To determine oxidative stress or DNA damage 
caused by the nanoparticles, B35 cells were seeded overnight in a Cyntellect LEAP plate 
at 5 x 10
5
 cells/mL (2500 cells/well in 384-well plate) in DMEM with 10% FBS. Varying 
concentrations of nanoparticles in PBS or vehicle was added to the cells and incubated 
for 24 hours. 150 uM of acrolein and 150 uM hydrogen peroxide were used as positive 
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controls for oxidative stress. Before running the experiment, the optimal dye 
concentration was determined using untreated cells and cells treated with the positive 
controls. After 24 hours, the cells were washed with PBS three times, and they were 
incubated in 10 uM DHE for 30 minutes. The excess dye was washed away, and the cells 
were analyzed in DMEM with 10% FBS and 5 ug/mL Hoechst 33342 using Cyntellect's 
Laser-Enabled Analysis and Processing (LEAP) image cytometer. The analysis settings 
were optimized using the positive and negative controls before obtaining data from all 
samples. The data was exported for post-processing in Excel. Images were processed 
using ImageJ (NIH, Bethesda, MD). C8-B4 cells were seeded at 2x10
5 
cells/mL (2000 
cells/well in 384-well plate) and processed similarly for toxicity experiments. 
 
4.2.5 Cytotoxicity analysis by LEAP 
To determine specific viability of the cells after nanoparticle incubation, B35 cells were 
seeded overnight in a Cyntellect LEAP plate at 5 x 10
5
 cells/mL in DMEM with 10% 
FBS. Varying concentrations of nanoparticles in PBS or vehicle was added to the cells 
and incubated for 24 hours. 150 uM of acrolein was used as a positive control. Before 
running the experiment, the optimal dye concentrations were determined using untreated 
cells and cells treated with the positive control. After 24 hours, the cells were washed 
with PBS three times, and they were incubated in 2 uM calcein am green for 30 minutes. 
The excess dye was washed away, and the cells were analyzed in DMEM with 10% FBS 
and 5 ug/mL Hoechst 33342 using LEAP. The analysis settings were optimized using the 
positive and negative controls before obtaining data from all samples. The data was 
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exported for post-processing in Excel. C8-B4 cells were seeded at 2x10
5 
cells/mL (2000 
cells/well in 384-well plate) and processed similarly for toxicity experiments. 
 
4.2.6 Near-infrared fluorescent (NIRF) labeling of nanoparticles 
As synthesized nanoparticles were vortexed with 1:10 molar ratio of CF 680:PEG 
(Sigma, St. Louis) for 2 hours in the dark before undergoing dialysis overnight to remove 
unreacted dye. 
 
4.2.7 Nanoparticle uptake by confocal microscopy 
B35 cells were seeded overnight at 5 x 105 cells/mL in 35 mm Fluorodishes. Vehicle or 
350 ug/mL nanoparticles in PBS was added to the cells and incubated for 24 hours. After 
the incubation period, the cells were washed three times with PBS, and the cells were 
fixed in 4% paraformaldehyde (PFA) for 25 minutes and subsequently washed three 
times. They were permeabilized with 0.1% Triton X-100 for 5 minutes and washed 
before staining with 5 uL of phalloidin Alexa Fluor 488 (Invitrogen) in 1% blocking 
buffer for 30 minutes. In the last ten minutes, 300 ng/mL propidium iodide (PI, 
Invitrogen) was added as a counterstain. The excess dye solution was removed, and 
Vectashield was added to the dishes. 
 
Confocal images were obtained using and Olympus Fluoview at 20X set with the 
appropriate filters for Alexa Fluor 488 using a 488 nm laser, PI using a 543 nm laser, and 




4.2.8 Oxidative stress analysis by LEAP in co-culture model 
To determine oxidative stress or DNA damage caused by the nanoparticles, B35 and C8-
B4 cells were seeded overnight in a Cyntellect LEAP plate at 1.4 x 10
5
 cells/mL and 6 x 
10
4
 cells/mL (1680 cells/well and 720 cells/well in 384-well plate), respectively, in 
DMEM with 10% FBS. Therefore, about 30% of the original population of each sample 
was C8-B4 cells, optimized before the experiment. Additional wells using only B35 cells 
and C8-B4 cells were also seeded at 2x10
5
 cells/mL (2400 cells/well). Varying 
concentrations of nanoparticles in PBS was added to the cells and incubated for 24 hours. 
200 uM hydrogen peroxide was used as positive control for oxidative stress. Before 
running the experiment, the optimal dye concentration was determined using untreated 
cells and cells treated with the positive controls. After 24 hours, the cells were washed 
with PBS twice, and they were incubated in 10 uM DHE for 30 minutes. The excess dye 
was washed away, and the cells were analyzed in DMEM with 10% FBS and 10 ug/mL 
Hoechst 33342 using LEAP. The analysis settings were optimized using the positive and 
negative controls before obtaining data from all samples. The data was exported for post-
processing in Excel. Images were processed using ImageJ (NIH, Bethesda, MD). 
 
4.2.9 Cytotoxicity analysis by LEAP in co-culture model 
To determine specific viability of the cells after nanoparticle incubation, B35 and C8-B4 
cells were seeded overnight in a Cyntellect LEAP plate at 1.5 x 10
5
 cells/mL and 5 x 10
4
 
cells/mL (1680 cells/well and 720 cells/well in 384-well plate), respectively, in DMEM 
with 10% FBS. Therefore, about 30% of the original population of each sample was C8-
B4 cells, optimized before the experiment. Additional wells using only B35 cells and C8-
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B4 cells were also seeded at 2x10
5
 cells/mL (2400 cells/well). Varying concentrations of 
nanoparticles in PBS or vehicle was added to the cells and incubated for 24 hours. Before 
running the experiment, the optimal dye concentrations were determined using untreated 
cells and cells treated with the positive control. After 24 hours, the cells were washed 
with PBS twice, and they were incubated in 2 uM calcein am green for 30 minutes. The 
excess dye was washed away, and the cells were analyzed in DMEM with 10% FBS and 
10 ug/mL Hoechst 33342 using LEAP. The analysis settings were optimized using the 
positive and negative controls before obtaining data from all samples. The data was 
exported for post-processing in Excel. 
 
4.2.10 Statistical analysis 
To determine statistical significance, ANOVA was performed on each data set. For pair-
wise comparisons, a test using the Least Significant Difference (LSD) was used. P-values 
less than 0.01 were considered significant. 
 
4.3 Results and discussion 
4.3.1 LDH assay for nanoparticle toxicity 
An additional important factor in using a nanoparticle-based delivery system is the 
potential toxicity of the delivery system. Particularly for silica nanoparticles, some 
studies have shown cytotoxic effects. Because a neuron's membrane is essential to its 
function, the lactate dehydrogenase activity assay was chosen to measure toxicity. As the 
membrane integrity of the cells are compromised, the protein escapes from the 
cytoplasm. Therefore, higher activity indicates a higher level of membrane damage in the 
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cell population. Triton X-100 was chosen as the positive control, and the cells within 
those wells had lysed after the incubation period. The LDH activity is measured relative 
to the lysed cells as described in the methods (Figures 4.1 and 4.2). Even at high 




Figure 4.1. Membrane integrity measurement by LDH in B35 cells incubated with 
mPEG-amine nanoparticles for 24 hours. None of the concentrations showed significant 
damage from the control (P > 0.01). 
 
After 24 hours, the nanoparticles did not induce significant damage to the cells. Even at 
high concentrations, the cells' membranes remained intact. Upon microscopic 
examination, the cells maintained their morphology, including dendrite-like processes 
(data not shown), rather than rescinding their processes and changing cell body 
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mPEG-Amine Toxicity after 24 h in B35 cells
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rather than single cells, though, it is limited in its scope. Therefore, it is imperative to 




Figure 4.2. Membrane integrity measurement by LDH in B35 cells incubated with 
mPEG-hydrazide nanoparticles for 24 hours. None of the concentrations showed 
significant damage from the control (P > 0.01). 
 
4.3.2 Reactive oxygen species (ROS) generation 
 
To overcome the weakness of the LDH assay, dihydroethidium (DHE) was used to 
monitor cells that were incubated with nanoparticles. After incubation, the nanoparticles 
were removed, and the cells were stained with DHE and Hoechst. DHE reacts with ROS 
and upon intercalation with DNA, it has a red emission spectra. Laser-scanning 
cytometry via LEAP counts and records the characteristic for each cell, giving a detailed 
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Figure 4.3. ROS production from mPEG-amine nanoparticles measured via 
dihydroethidium (DHE) fluorescence and analysis by LEAP. Nanoparticles were 
incubated for 24 hours. None of the concentrations showed significant damage from the 
control (P > 0.01). 
 
Similar to the LDH assay, the results using DHE show very little oxidative stress induced 
by the mPEG-amine nanoparticles (Figures 4.3 and 4.4). More than likely, their small 






































Figure 4.4. ROS production from mPEG-hydrazide nanoparticles measured via 
dihydroethidium (DHE) fluorescence and analysis by LEAP. Nanoparticles were 
incubated for 24 hours. None of the concentrations showed significant damage from the 
control (P > 0.01). 
 
For comparison, images of control wells and nanoparticle wells are shown in Figure 4.5. 
Even at the high concentrations, the nanoparticles did not induce oxidative stress, which 
is important if they are to be used for targeting oxidative stress in clinical applications. 
The cell number in the acrolein sample had obviously dropped drastically, and nearly half 
of the cells were DHE-positive. Additionally, it is interesting to note the extensive 







































Figure 4.5. Representative nanotoxicity LEAP images. Cells were incubated for 24 hours 
with various compounds and stained with Hoechst 33342 (blue) and DHE (red). 
 
4.3.3 Cell viability after nanoparticle incubation 
To look at toxicity further, viability was determined using calcein AM, a live-cell dye, 
and Hoechst 3342, a nucleic acid dye for a total cell count. The cells were incubated with 
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Figure 4.6. Cell viability and cell number of B35 cells after being exposed to mPEG-
amine nanoparticles for 24 hours. The samples with nanoparticles do not show a 
significant decrease in viability. The cell number also remains consistent. (mean ± SE; P 
> 0.01) 
 
Like the previous experiments, the mPEG-amine nanoparticles showed no significant 
change in viability after the 24-hour period, even at the highest concentrations (Figure 
4.6). The nanoparticles also did not affect the viability of the neuronal cells. More 
importantly, though, the cell population was consistent with the untreated cells. 
Oftentimes, a high viability may be seen in a whole cell population, but likely these cells 
have undergone "survival of the fittest" since missing cells may simply disappear through 
apoptosis or violent, explosive necrosis. It is crucial to ensure that the cell population is 
not only healthy but also still present to prevent such artifacts in experiments. Different 



























































Figure 4.7. Cell viability and cell number of B35 cells after being exposed to mPEG-
hydrazide nanoparticles for 24 hours. The samples with nanoparticles do not show a 
significant decrease in viability. The cell number slowly decreases with an increase in 
concentration, though, indicating a change in cell health and growth. (mean ± SE; *P < 
0.01) 
 
The cell viability does not decrease, but the cell number steadily drops as the nanoparticle 
concentration increases. The drop becomes significant in the cells incubated with 400 
ug/mL of nanoparticles. The cell growth may be stifled from the large quantity of 
nanoparticles, or, in a more likely case, they are dying. If they undergo apoptosis, their 
contents will be packaged and exported, or death via necrosis may cause the cells to 
essentially "explode;" both cases would account for a decrease in cell number without 
adversely affecting the overall viability, as one cannot count what is not present. The 
drop becomes significant in the cells incubated with both 400 ug/mL and 500 ug/mL of 



























































stifled. The high viability of the 500 ug/mL sample exemplifies seeing a high viability 
number merely from the hardiest cells surviving, and demonstrates the importance of 
single-cell analysis techniques.  
 
A possible explanation for the difference in the cell response to the two different 
nanoparticles likely stems from the difference in the two PEG products. The products are 
from two different manufacturers with different methods of PEG modification and 
purification. Upon first adding the hydrazide nanoparticles to the cells, the aggregate in 
the media so much that it can be seen under low magnification. The mPEG-Am 
nanoparticles and lower concentrations of mPEG-Hz nanoparticles does not have the 
same effect. Beyond that, hydrazides are often used for their "click" chemistry 
capabilities. At high levels of the nanoparticles, it could possibly interfering with 
membrane proteins or signaling. Regardless, the amount of nanoparticles used in the 
experiment are unrealistically high levels for the amount of cells (7.5 ug nanoparticles per 
5000 cells at the highest concentration). 
 
4.3.4 Nanoparticle uptake via confocal microscopy 
For the purpose of delivery, it is important that the nanoparticles affiliate with the cells of 
interest. In an in vitro setting, the cells are incubated with the nanoparticles for a period 
of time and the cells are explored for the presence of nanoparticles. In this study, 
nanoparticles were labeled with a near-infrared fluorescent (NIRF) dye similar to Cy5.5, 
CF 680, and incubated with nanoparticles for 24 hours. The labeling of the nanoparticles 
requires easy "click" chemistry without the introduction of other reagents. Furthermore, 
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upon seeing success in vitro, the same dye is often used in vivo for studying nanoparticle 
distribution.[142] 
 
Figure 4.8 shows representative images obtained from confocal microscopy. Actin was 
stained with phalloidin Alexa Fluor 488 (green) while the nuclei were stained with 
propidium iodide (blue). As a comparison, the bright field images and NIRF-channel 
(magenta) images are shown for comparison for both the control and the cells incubated 
with nanoparticles. Population of the nanoparticles were seen in various planes and were 
seen inside the cells, as opposed to sticking to the outside. The bright field images are 
qualitative and show that the overall morphology of the cells is maintained, even after 
incubation with the nanoparticles. The current resolution of such microscopy will not 
distinguish single nanoparticles, but signals from aggregates within a cell population can 
be found. This limitation is inherent in studying nanoparticles, and silica-based 






Figure 4.8. 20X magnification of cells incubated with PBS (left) and 350 ug/mL of 
nanoparticles (right) for 24 hours. (Top) Bright field images, (middle) NIRF channel 
showing nanoparticle aggregates, and (bottom) merged image. Actin is seen in green, 
nuclei are blue, and nanoparticle aggregates within the cells are shown in magenta. 






4.3.5 ROS generation in C8-B4 cells 
C8-B4 cells are a microglial cell line with macrophage markers and characteristics. They 
were obtained from mice and have been shown to have phagocytic properties.[143] 
Determining how the macrophage-like cells react to nanoparticles is important for 
clinical translation. Upon activation, such cells release inflammatory factors, ROS, and 
RNS.[144] 
 
C8-B4 cells were exposed to mPEG-Hz nanoparticles for 24 hours and stained with DHE 
and Hoechst 33342 (Figure 4.9). The cells reacted negatively to the nanoparticles, despite 
the PEG coating. The amount of ROS increased significantly as the amount of 
nanoparticles increased. A similar experiment with only PEG did not produce such a 






Figure 4.9. ROS production in C8-B4 cells after exposure to mPEG-Hz nanoparticles. All 
but the lowest concentration affected the response of the cells. ROS production was 
increased, suggesting activation of the microglial cells. (mean ± SE; *P < 0.01) 
 
4.3.6 C8-B4 cell viability after nanoparticle incubation 
The microglial cells showed an increase production of ROS with the nanoparticles. It was 
critical to look at their viability (Figure 4.10). The viability of the cells decreased 
significantly as the nanoparticle concentration increased. The cell number was mostly 
consistent, with the exception of the largest concentration. Contrary to the response from 
the B35 cells, there is a larger amount of dead cells within the population rather than 
demonstrating a high viability and low cell number. The concentrations affecting the C8-
B4 cells were much lower than those that affected the B35 cells, showing a increased 












































Figure 4.10. Viability and cell number of C8-B4 cells after exposure to nanoparticles. 
Similar to the ROS results, all but the lowest concentration affected the viability, but cell 
number was only affected in the highest concentration. (mean ± SE; *P < 0.01) 
 
Figure 4.11 contains the LEAP images obtained for the C8-B4 cells. The increase in ROS 
production at 100 ug/mL of nanoparticles is clearly evident, as is the significant decrease 
in cell number. Morphologically, the C8-B4 cells become more rounded and larger, likely 
from "eating" large numbers of nanoparticles. Additionally, if the cells are dying from 
exposure to the nanoparticles, they may be "eating" the dead cells. Additional studies, 
such as confocal microscopy, may give an indication of what is causing activation: the 

































































Figure 4.11. LEAP images of C8-B4 cells incubated with nanoparticles for 24 hours. 
ROS increases with the nanoparticle concentration, and cell number decreases. 
 
4.3.7 ROS generation in co-culture of B35 and C8-B4 cells 
ROS was produced in C8-B4 cells upon incubation with the nanoparticles. A co-culture 
model was devised with 30% of seeded cells containing the C8-B4 cells, and the 
remaining cells were the B35 neurons. Similar concentrations were used at those used 
with only C8-B4 cells: 25 ug/mL-100 ug/mL. Similar to the results with C8-B4 cells, all 
of the concentrations produced some ROS, with the exception of the lowest concentration 
of 25 ug/mL (Figure 4.12). The ROS level was much lower than that seen in just the C8-
B4 cells, but the production of ROS could lead to problems with the normal cells. 







Figure 4.12. ROS response to nanoparticles after 24 hours in co-culture with B35 neurons 
and C8-B4 microglial cells. Thirty percent of seeded cells were C8-B4 cells. ROS was 
affected in all but the lowest concentration of nanoparticles used. (mean ± SE; *P < 0.01) 
 
4.3.8 Cell viability in co-culture after nanoparticle incubation 
Beyond looking at the ROS production, the viability and cell number were also studied in 
the co-culture model. The C8-B4 cells had a decrease in both, but in the co-culture 
model, no significant effects were observed (Figure 4.13). In the case of the co-culture 
model, two factors are likely involved in the reduced response. First, the amount of 
microglial cells is significantly lower. Additionally, the neurons are likely taking in the 
nanoparticles, reducing the amount for the microglial cells to uptake and react to 




































Co-culture (B35/C8-B4) ROS response to 





needed for therapeutic delivery. The LEAP images in Figure 4.14 show the slight 
increase in ROS observed. 
 
 
Figure 4.13. Viability and cell number in co-culture model after nanoparticle exposure. 
None of the concentrations used significantly affected the viability or the cell number. 
The number of neuronal cells versus microglial cells likely reduced the negative response 
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Figure 4.14. LEAP images of co-culture incubated with nanoparticles for 24 hours. The 
ROS levels increase significantly, but viability and cell number were not affected. 
 
4.4 Concluding summary 
Toxicity experiments have indicated little toxicity to B35 cells after 24 hours. Based on 
the studies, the largest concentrations of the mPEG-hydrazide nanoparticles affect the 
overall cell number, but do not decrease overall viability or cause high levels of ROS 
production. Furthermore, the nanoparticles were found within the cells after a 24-hour 
period. In the case of injured cells with compromised membranes, uptake would present 
less of an issue, but if the nanoparticles were to translate for other applications, crossing 
into cells would be important. 
 






In similar experiments with microglial cells, the immune cells of the CNS, a significant 
response was observed at concentrations much less than those used for the B35 cells. 
High levels of ROS were observed, and both viability and cell number decreased. In a co-
culture model with both types of cells, ROS was affected, but cell number and viability 
were not. Fortunately, the numbers used were lower than those needed for therapeutic 
delivery. 
 
With the current knowledge, though, any in vivo studies would have to account for a 
potential immune response that could be elicited by the nanoparticles. The model may 
also be useful for studying different nanoparticle formulations. Determining a 
nanoparticle formulation that reduces the negative response would give an indication of 
efficacy early in a study. Additional discussion can also be found in the reference by 




CHAPTER 5. AIM III: EXPLORE NATURAL PRODUCTS AS POTENTIAL 
ACROLEIN SCAVENGERS
5.1 Introduction 
Catechins are complex, natural flavanoid molecules found in various plant products.  The 
most abundant source of catechins are extracted from green tea leaves, but they are also 
found in wines and fruits in lower concentrations. Catechins are related via two adjoining 
rings connected to a separate benzyl alcohol, but differ in the hydroxylation on the B ring 




















Figure 5.1 Basic structure of catechin (above) and table of common catechin derivatives. 
Chirality not shown. 
 
Various work has looked at the properties of catechins, mainly of EGCG, as it is the most 
abundant catechin in green tea extracts. The major focus has been to study their strong 
Name Abbrev. R
1
 (C ring) R
2
 (B ring) R
3 
Catechin C -OH -H -OH 
Epicatechin EC -OH -OH -H 
Epigallocatechin EGC -OH -OH -OH 
Epicatechin gallate ECG Gallate ester -OH -OH 
Epigallocatechin gallate EGCG Gallate ester -OH -OH 
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antioxidant and anti-inflammatory properties. Specifically, the heavily substituted C ring 
can be oxidized, forming quinone-like molecules, thus preventing the oxidation of critical 
proteins and structures in a cell.[146, 147, 148, 149] Along with their promising 
antioxidant ability, they exhibit extremely low toxicity and are classified as GRAS 
products. 
 
Although they exhibit these characteristics, the exact mechanisms of action are elusive. 
Additionally, their metabolism produces many metabolites and has various methods of 
uptake in vivo. Generally, their half life is a short three hours.[146, 150, 151] To try to 
increase the availability and activity of the catechins, various groups have modified and 
studied the activity of new compounds made from a catechin. Most of the conjugations 
occur using an enzyme catalyst, such as horseradish peroxidase or laccase, which allows 
the catechin to form a Schiff base with an amine-containing compound or form polymeric 
chains. For instance, groups have conjugated catechin to various polymers or structures. 
[152, 153, 154, 155] In other studies, researchers have synthesized polymeric 
catechins.[156, 157, 158, 159, 160] 
 
For the purpose of the current research, catechins may help alleviate symptoms of 
acrolein-induced oxidative stress. Catechins, specifically EGCG, have been shown to 
react and reduce acrolein and similar ROS compounds effectively.[149, 161, 162] If one 
proves to be a more successful scavenger of acrolein for spinal cord injury, it may open a 




5.2 Materials and methods 
5.2.1 B35 rat neuroblastoma cell culture 
B35 rat neuroblastoma cells were obtained from ATCC (American Tissue Culture 
Collection) and cultured in T-25 or T-75 flasks with DMEM (ATCC) supplemented with 
10% FBS (Invitrogen). The cells were co-cultured twice per week and were seeded in 
concentrations from 1:4 to 1:8. For all experiments, cells were used in the  log phase of 
growth. 
 
5.2.2 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging 
To evaluate free radical scavenging capability, effectiveness against 2,2-diphenyl-1-
picrylhydrazyl (DPPH), a stable free radical, was measured. DPPH forms a dark purple 
solution with a peak absorbance at 517 nm. A stock solution of DPPH was prepared in 
ethanol. Catechin hydrate, epigallocatechin gallate (EGCG), and hydralazine were all 
purchased from Sigma and used as received. Solutions of each compound were prepared 
in bubbled PBS. For each reaction, done in three replicates, 50 µL of DPPH in ethanol 
was added to 50 µL of catechin, EGCG ,or hydralazine for a final DPPH concentration of 
200 µM. The reactions were shaken at room temperature in the dark for 45 minutes 
before the absorbance was read at 517 nm and 690 nm using a VersaMax microplate 
reader (Molecular Devices, LLC, Sunnyvale, CA). The concentration of each reaction 
was calculated using a standard curve of DPPH in 1:1 (v/v) of ethanol/PBS. The 
scavenged percentage was calculated as follows: 
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5.2.3 Lactate dehydrogenase (LDH) assay for membrane integrity 
Epigallocatechin gallate was purchased from Sigma and used as received. A stock 
solution of EGCG was prepared and bubbled in sterile ethanol. Directly before use, the 
stock was diluted to the appropriate concentrations in PBS. To determine if EGCG is an 
effective scavenger of acrolein, the LDH Toxicology Kit was purchased from Sigma and 
used per the manufacturer's instructions. B35 cells were seeded in triplicates at 5 x 10
5
 
cells/mL in DMEM with 10% FBS overnight. A freshly-prepared solution of acrolein in 
PBS was added to the cells and incubated for 30 minutes before the addition of EGCG. 
The vehicle used for the controls contained the highest EtOH concentration based on the 
dilution of EGCG, which was less than 1.5%. After 4 hours with EGCG, the LDH 
activity was measured using a VersaMax microplate reader (Molecular Devices, LLC, 
Sunnyvale, CA) To determine the total LDH amount, a set of untreated cells were lysed 
using 0.5% Triton-X. The data is reported as a change of LDH activity compared to the 
lysed control wells, calculated as follows: 
                     
           
                       
     
 
5.2.4 Statistical analysis 
To determine statistical significance, ANOVA was performed on each data set. For pair-
wise comparisons, a test using the Least Significant Difference (LSD) was used. P-values 





5.3 Results and discussion 
5.3.1 DPPH scavenging 
In order to evaluate the each compound's ability to quench free radicals, the change in 
DPPH concentration was measured in various reactions with each compound. In solution, 
DPPH remains a dark purple color until being quenched, where it turns yellow. Because 
the reaction with EGCG occurs very rapidly, low molar ratios were chosen to evaluate 
the compounds against a larger amount of DPPH. 
 
Figure 5.2 shows the free radical quenching of each compound. The inset shows a typical 
standard concentration curve for DPPH. Only at the two highest concentrations of 20 and 
40 µM were all three compounds able to remove a significant amount of DPPH after 45 
minutes. EGCG removed significantly more DPPH at all concentrations, with the 
exception of 40 µM, where hydralazine and EGCG were not significantly different. 
Catechin hydrate and hydralazine had similar performances. Compared to the other two 
molecules, EGCG has higher nucleophilic capabilities with an increasing number of 
hydroxyl groups that can donate electrons and be stabilized with π-bonds from the 






Figure 5.2. DPPH Scavenging with catechin, EGCG, and hydralazine. Different 
concentrations of catechin, EGCG, and hydralazine were reacted with 200 µM of DPPH 
for 45 minutes. The absorbance of DPPH at 517 nm was measured. The inset shows a 
representative standard curve used to calculate the remaining DPPH concentration. 
Displayed is the mean of three reactions + SE. There were no significant differences 
between hydralazine and catechin. 
 
5.3.2 Evaluating efficacy using the LDH assay 
Especially for acrolein scavenging, maintaining membrane integrity is vital for keeping 
cells healthy. To determine if catechin or EGCG could prevent damage by acrolein, cells 
were incubated with acrolein for 30 minutes before the addition of treatment, which was 
left for four hours (Figures 5.3 and 5.4). For comparison, the data for hydralazine is 
shown in conjunction with catechin. Hydralazine prevented damage by acrolein while 
catechin showed no benefit against acrolein. A similar experiment with catechin being 
applied both before and after exposure to the same hydrogen peroxide concentration did 
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Figure 5.3. Acrolein scavenging with catechin and hydralazine via LDH. Acrolein was 
added to the cells before the addition of treatment. Catechin showed no benefit against 
acrolein, unlike hydralazine. 
 
In a similar experiment, all of the samples containing EGCG were similar to the vehicle 
control whereas the untreated cells exposed to acrolein had significant damage. The 
results indicate that EGCG was able to prevent damage to the cells (Figure 5.4). Such 
results are likely due to the high scavenging ability of EGCG compared to other 
catechins, which has been shown previously.[149, 162] Therefore, in later studies, EGCG 















































Figure 5.4. Acrolein scavenging with EGCG via LDH. 50 uM of acrolein was added to 
B35 cells for 30 minutes before the application of EGCG for 4 hours. All concentrations 
were able to prevent acrolein from causing intense damage and cell death. 
 
5.4 Concluding summary 
Two natural products, catechin and epigallocatechin gallate, were explored for their 
ability to prevent cell damage via acrolein. Although catechin outperformed hydralazine 
in a free radical assay, against acrolein, it did not provide any benefit whereas both 
hydralazine and EGCG significantly reduced damage caused by acrolein. In future 
studies, both hydralazine and EGCG will be used to determine if their efficacy and 












































CHAPTER 6. AIM IV: EXPLORE THERAPY-NANOPARTICLE INTERACTIONS 
IN A CELL-FREE SYSTEM
6.1 Introduction 
Before adding nanoparticles to a complicated cell system, demonstrating the ability of the 
nanoparticles to act as a vehicle system for therapeutic delivery is essential. The 
experiments in this aim were used to determine whether the therapeutic would interact 
with the nanoparticles. Once an interaction could be established, it is necessary to 
determine how the interaction affects the nanoparticles, particularly their size 
distribution. 
 
6.2 Materials and methods 
6.2.1 Reflective hyperspectral imaging for hydralazine loading of mPEG-amine 
nanoparticles 
 
For hydralazine loading, 3 mg of the synthesized mPEG-Am in PBS was shaken with 75 
mM solution of hydralazine hydrochloride (Sigma, St. Louis)  in PBS. Samples for 
reflective hyperspectral imaging (RHI) were sent to Cytoviva, Inc in Arab, AL. Samples 
of 75 mM hydralazine, mPEG-amine nanoparticles, and hydralazine-loaded nanoparticles 
were analyzed and the spectra were obtained and compared. Hydralazine and mPEG-




6.2.2 Size of loaded nanoparticles 
 
Solutions of 1 mg/mL of nanoparticles were loaded with hydralazine (1600 ug/mL, 25% 
EtOH) at concentrations of 0 ug/mL, 100 ug/mL, 250 ug/mL, and 500 ug/mL, 
corresponding to 0, 10, 25 and 50-percent loading by mass. The hydrodynamic diameter 
of the nanoparticle population was measured using a Malvern Zetasizer ZS. An average 
of three measurements was used to determine the average hydrodynamic diameter. 
 
6.3 Results and discussion 
6.3.1 Reflective hyperspectral imaging for hydralazine loading of mPEG-amine 
nanoparticles 
 
Hydralazine has been shown to scavenge for acrolein; therefore, loading the nanoparticles 
provides a therapy that will stop the secondary injury cascade, which affects both the 
injured and surrounding healthy tissue, caused by acrolein. Reflective hyperspectral 
imaging was used to confirm loading of hydralazine. A sample of the nanoparticles 
loaded with hydralazine was analyzed for the presence of the drug. When the sample was 
mapped, no unassociated nanoparticle could be found in solution, indicating a successful 
interaction with the nanoparticles (Cytoviva, email communication). The spectra are 
shown in Figure 6.1. The mixture of hydralazine with the nanoparticles shows 
characteristics of both the pure drug and the nanoparticles. Because there is free 







Figure 6.1. Spectra of hydralazine-loaded nanoparticles via reflective hyperspectral 
imaging. X-axis shows wavelength from 400-1000 nm. The right spectrum is the mPEG-
Am nanoparticles; the left spectrum is that of hydralazine, and the middle spectrum is the 
mixture of the two. Image and analysis provided by Cytoviva, Inc. (Arab, AL). 
 
6.3.2 Size of loaded nanoparticles 
Nanoparticles were diluted to a concentration of 1 mg/mL and loaded with a stock 
solution of hydralazine. The average hydrodynamic diameter and PDI is shown in Table 
6.1. As the concentration of hydralazine increased, the size of the nanoparticles increased. 
Based on how the average diameter is calculated, the 25% loaded sample shows an 
average of 34.4 nm, but the sample contained two populations of similar intensity: 18 nm 
and 56 nm. It is possible the concentration was similar to that in a buffered titration 
curve, and at 50% loading, it has overcome the threshold to have a more uniform 
distribution of nanoparticles with hydralazine. The PDI increases between the 10% and 







Drug in PBS spectral peak = 505nm 
peak (left)
MPEG-SNP in PBS spectral peak is = 
535nm peak (right)
MPEG-SNP + Drug in PBS spectral 
peaks exhibits characteristics of both 
(middle)










Table 6.1. Size of mPEG-Hz nanoparticles loaded with hydralazine. 
Loading (%) Diameter (nm) St. Dev. (nm) PDI 
0 14.18 2.23 0.262 
10 15.68 0.95 0.285 
25 34.40 2.41 0.302 
50 275.9 13.91 0.295 
 
6.4 Concluding summary 
The work presented in this aim demonstrates that the therapeutic interacts with the 
nanoparticles. Furthermore, the size of the nanoparticles interacting with various 
concentrations of hydralazine was investigated for future studies in vitro. In further 
studies, studies were performed only using mPEG-Hz nanoparticles loaded with 50% 
treatment by mass. 
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CHAPTER 7. AIM V: EVALUATE THE EFFICACY OF NANOPARTICLES IN 
VITRO.
7.1 Introduction 
Ultimately, the goal of the nanomedical system is the delivery of therapeutics for 
oxidative stress attenuation. In order to properly evaluate the performance of the 
nanoparticles, a proper in vitro system must be utilized. An important aspect of spinal 
cord injury is distinguishing between the original, primary injury, which is inevitable, and 
the secondary biological injury. In looking at the nanoparticle efficacy, it is important to 
evaluate the performance of the nanoparticle-therapy system against the therapy alone. 
This final aim describes the process of creating an appropriate in vitro model system for a 
primary-to-secondary injury followed by the evaluation of the original hypothesis: silica 
nanoparticles will improve the delivery of therapeutics. 
 
7.2 Materials and methods 
7.2.1 B35 rat neuroblastoma cell culture 
B35 rat neuroblastoma cells were obtained from ATCC (American Tissue Culture 
Collection) and cultured in T-25 or T-75 flasks with DMEM (ATCC) supplemented with 
10% FBS (Invitrogen). The cells were co-cultured twice per week and were seeded in 





7.2.2 C8-B4 mouse glioblastoma cell culture 
C8-B4 mouse glioblastoma cells were obtained from ATCC (American Tissue Culture 
Collection) and cultured in T-25 with DMEM (ATCC) supplemented with 10% FBS 
(Invitrogen). The cells were co-cultured twice per week and were seeded in 
concentrations from 1:3 to 1:4. For all experiments, cells were used in the  log phase of 
growth. 
 
7.2.3 Lactate dehydrogenase (LDH) assay for membrane integrity 
To confirm hydralazine as an effective scavenger of acrolein, the LDH Toxicology Kit 
was purchased from Sigma and used per the manufacturer's instructions. B35 cells were 
seeded in triplicates at 5 x 10
5
 cells/mL in DMEM with 10% FBS overnight. A freshly-
prepared solution of acrolein in PBS was added to the cells and incubated for 30 minutes 
before the addition of hydralazine.  After 4 hours, the LDH activity was measured using a 
VersaMax microplate reader (Molecular Devices, LLC, Sunnyvale, CA) To determine 
the total LDH amount, a set of untreated cells were lysed using 0.5% Triton-X. The data 
is reported as a change of LDH activity compared to the lysed control wells, calculated as 
follows: 
                     
           
                       
     
 
7.2.4 Primary stress model using Fe(II) 
B35 cells were seeded overnight in a 96-well Cyntellect LEAP plate at 4 x 10
5
 cells/mL 
in DMEM with 10% FBS. FeSO4 in DMEM was added to a final concentration of 100 
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uM incubated for 30 minutes before the addition of hydralazine, EGCG, or vehicle. After 
24 hours post iron exposure, the cells were washed with PBS twice, and they were 
incubated in 10 uM DHE and 2 uM calcein am  in PBS for 30 minutes. The dyes were 
washed away, and the cells were analyzed in DMEM with 10% FBS and 5 ug/mL 
Hoechst 33342. The analysis settings were optimized on LEAP using the positive and 
negative controls before obtaining data from all samples. The data was exported for post-
processing in Excel. 
 
7.2.5 Evaluating efficacy against LPO using DHE and cell viability 
B35 cells were seeded overnight in a 96-well Cyntellect LEAP plate at 4 x 10
5
 cells/mL 
in DMEM with 10% FBS. FeSO4 in DMEM was added to a final concentration of 20 uM 
incubated for 30 minutes before the addition of hydralazine, nanoparticles, hydralazine-
loaded nanoparticles, or EGCG-loaded nanoparticles. Four hours after the addition of 
iron, 15 uM acrolein was added in PBS. After 24 hours post iron exposure, the cells were 
washed with PBS twice, and they were incubated in 10 uM DHE and 2 uM calcein am  in 
PBS for 30 minutes. The dyes were washed away, and the cells were analyzed in DMEM 
with 10% FBS and 10 ug/mL Hoechst 33342. The analysis settings were optimized on 
LEAP using the positive and negative controls before obtaining data from all samples. 
The data was exported for post-processing in Excel. 
 
7.2.6 Evaluating cellular responses to loaded nanoparticles 
B35 cells were seeded overnight in a 96-well Cyntellect LEAP plate at 4 x 10
5
 cells/mL 
(20,000 cells/well) in DMEM with 10% FBS. Hydralazine, EGCG, hydralazine-loaded 
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nanoparticles, and EGCG-loaded nanoparticles were delivered using PBS and incubated 
for 24 hours. After 24 hours, the cells were washed with PBS twice, and they were 
incubated in 10 uM DHE and 2 uM calcein am  in PBS for 30 minutes. The dyes were 
washed away, and the cells were analyzed in DMEM with 10% FBS and 10 ug/mL 
Hoechst 33342. The analysis settings were optimized on LEAP using the positive and 
negative controls before obtaining data from all samples. The data was exported for post-
processing in Excel. 
 
7.2.7 Statistical analysis 
To determine statistical significance, ANOVA was performed on each data set. For pair-
wise comparisons within ANOVA sets, a test using the Least Significant Difference 
(LSD) was used. P-values less than 0.01 were considered significant. 
 
7.3 Results and discussion 
7.3.1 Confirming hydralazine as an acrolein scavenger 
Before beginning to evaluate the nanoparticles a proper model had to be established that 
would simulate how acrolein behaves in vivo. In the most basic model, acrolein was 
added directly to the cells, treatment was added after 30 minutes, and the membrane 
integrity was analyzed using the lactate dehydrogenase assay. Over a very short period, 






Figure 7.1. Acrolein attenuation with hydralazine. Membrane damage caused by acrolein 
was significantly decreased after incubation with hydralazine for 4 hours. (*P < 0.01) 
 
When the model was moved to more complex assays, though, it was found to be 
problematic. The ROS levels remained high (data not shown), indicating the cells were in 
the process of either recovering or dying. The LDH merely indicated fewer damaged or 
necrotic cells overall, but gave no indication of how the cells were dealing with the stress 
of the acrolein exposure. The model also lacked the "primary injury" aspect that would be 
found in a spinal cord injury or an MS attack. In the direct acrolein model, the compound 
was assumed to play the role of both the primary and secondary injury. 
 
7.3.2 Cell stress after exposure to Fe(II) 
To begin to address the shortcomings of the previous model, cells were exposed to 













































164, 165] If successful, the iron could be used to induce a "primary injury" followed by 
smaller doses of acrolein. Therefore, the cell behavior was evaluated after using only iron 




Figure 7.2. Hydralazine performance after ferrous iron exposure. Cells were exposed to 
iron(II) and then evaluated for ROS and viability. All samples were significantly different 
from the control for all parameters: viability, ROS, and total cell number. 
 
In the 24-hour assay, the cells had significantly higher levels of ROS, lower levels of 
viability, and fewer cells after exposure to the iron. The results are promising in that cells 
were dying, but the ROS level was not drastically high, which should change with 
exposure to acrolein. Hydralazine was only slightly affective against the iron exposure. 
The higher concentrations were detrimental, and only the lowest concentration was 
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Figure 7.3. EGCG performance after ferrous iron exposure. Cells were exposed to 
iron(II) and then evaluated for ROS and viability. All samples were significantly different 
from the control for all parameters: viability, ROS, and total cell number. 
 
Alternately, the EGCG had a mostly neutral performance against the iron exposure. 
Similar to the higher hydralazine concentrations, the EGCG was detrimental to the cell 
population, and the highest (75 uM) actually increased the ROS level in the cell 
population. The overall viability increased, but the it merely indicates that dead cells had 
likely undergone apoptosis rather than remaining dead in the well (necrotic) in the 
positive control. Overall, the iron caused a significant amount of cellular loss and death 
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7.3.3 Iron and acrolein in vitro model 
The next in vitro model first utilized the iron to induce a "primary" injury followed by a 
dose of acrolein for "secondary" injury. The acrolein was added on a 4-hour delay after 
the iron exposure based on previous work indicating that acrolein levels rise over a 24-
hour period in vivo.[166] In the experiments involving nanoparticles, nanoparticles were 
loaded 50% by mass with the therapy of interest. The final concentration of therapy 
added to the cells was converted to mass by volume to determine the appropriate mass of 
therapy and nanoparticles to be incubated together. For instance, in the 2.5 uM 
hydralazine sample, the hydralazine mass/volume is 0.2 ug/mL. Therefore, 0.2 ug/mL of 
hydralazine was loaded in 0.4 ug nanoparticles/mL for the concentration corresponding to 






Figure 7.4. Delayed acrolein model using hydralazine and hydralazine-loaded 
nanoparticles. The change in cell number indicates an interaction between hydralazine 
and the nanoparticles. (Symbols indicate P < 0.01.)  
 
In the experiment with hydralazine and hydralazine-loaded nanoparticles, the viability 
and ROS changed little in the treatment samples, but the cell number varied with the 
hydralazine level (Figure 7.4). In the samples with nanoparticles, the cell number does 
not improve with the application of treatment. The two lowest hydralazine concentrations 
showed a significant increase in cell number before declining again. Based on the 
controls, the empty nanoparticles did not change the cell number in either the negative 
(vehicle) or positive controls. On a separate note, the model shows that the iron and 
acrolein concentrations used affected the cell population slightly, but using both of them 
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Therefore, it is hypothesized that some interaction between the nanoparticles and 
hydralazine changed the behavior of the hydralazine to affect the cell population. More of 
the cells are dying, which could be from very slow drug release. In the case of this model, 
a bolus dose of acrolein is added to the cells. Since the nanoparticles are not delivering a 
bolus dose of therapy, it could reasonably be explained that the cells will continue to die 
from the iron and acrolein exposure until they receive a reasonable amount of therapy to 
prevent cell death. Either higher nanoparticle concentrations or a slower dose of acrolein 
may be necessary to properly assess the nanoparticle behavior. 
 
 
Figure 7.5. Delayed acrolein model using EGCG and EGCG-loaded nanoparticles. The 
cell number in all nanoparticle samples was significantly different from the positive 
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The results with EGCG were more complex than those of hydralazine-loaded 
nanoparticles. (Figure 7.5) Similarly, though, the empty nanoparticles did not affect the 
cell population. In the nanoparticle-treated samples, the viability and cell number 
decreased compared to the positive control. The cell number leveled, but the viability 
continued to decrease. Additionally, the ROS in the two highest concentrations with 
nanoparticles was significantly increased compared the positive control. (Figure 7.6) 
Overall, the experiment did not show any benefit in using EGCG, but the nanoparticles 
changed the cell behavior even more significantly. One explanation for the poor EGCG 
results could stem from its apoptotic and pro-oxidant activity seen in cancer cells, which 
would obviously confound the study.[147] If that is the case, the nanoparticles may be 







Figure 7.6. ROS of delayed acrolein model using EGCG and EGCG-loaded 
nanoparticles. EGCG-loaded nanoparticles in the highest concentrations adversely 
affected the recovery of the cells, creating more oxidative stress. (Symbols indicate P < 
0.01.) 
 
7.3.4 Cellular responses to loaded nanoparticles 
Because the nanoparticles showed no advantage over the treatments alone, various 
problems may account for the lack of efficacy: 
 
 1)  The interaction of the nanoparticles and the therapeutic negatively affects the 
cell behavior through a change in either a physical or chemical characteristic. 
 2) The nanoparticles may be releasing the treatment too slowly to overcome the 
bolus dose of acrolein in the models, resulting in an increase in cell death before the 
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which can become a pro-oxidant and pro-apoptotic compound at high enough 
concentrations, negatively affecting the cells even further. 
 3) The cell model is not ideal for the type of in vivo problem that is being 
simulated. 
 4) The nanoparticles may need to be improved through a different synthesis 
method, their size, or some other characteristic. 
  
In an attempt to test first of these hypotheses, the cells were incubated with the treatments 
and treatment-loaded nanoparticles and toxicity assays were performed after 24 hours. 
The results for hydralazine are shown in the Figure 7.7. The cells incubated with 
hydralazine-loaded nanoparticles behaved no differently than those exposed only to 







Figure 7.7. Viability and cell number from the interaction of hydralazine and the 






























































Figure 7.8. ROS results from the interaction of hydralazine and the nanoparticles. None 
of the concentrations showed differences that were statistically significant. 
 
The interaction was not detrimental to the cells, but it does not address the hypothesis that 
the nanoparticles may be releasing the treatments slowly, both extending their activity 
and keeping the concentration too low to be beneficial against acrolein. On the other 
hand, the experiment with EGCG proved slightly different (Figures 7.9 and 7.10). At 
high concentrations, EGCG can become a pro-oxidant rather than an antioxidant. 
Additionally, in solution, EGCG will polymerize or undergo modifications. For most of 
the concentrations, the EGCG was not problematic. With EGCG alone, 50 uM was 
detrimental to cells in both ROS production and cell number. The next lowest 
concentration, 37.5 uM was detrimental only to the cell number. On the other hand, at 
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a higher pro-oxidant activity when loaded into the nanoparticles, and the cell number was 
decreased, which was similar to the free EGCG. 
 
 
Figure 7.9. Viability and cell number after 24 exposure to EGCG-loaded nanoparticles. 
The cell number was decreased in all samples with 37.5 uM and 50 uM EGCG, including 
those with nanoparticles. 
 
The nanoparticles may be protecting the EGCG from degradation. Additionally, it is 
more difficult to predict the response of a therapeutic when the cells are likely taking up 
the nanoparticles. With cells "eating" the nanoparticles, the effective concentration may 
be higher in some of the cells than in others. It would increase the EGCG concentration 


















































Figure 7.10. ROS production of EGCG-loaded nanoparticles. ROS was increased in the 
50 uM, EGCG-only sample, but the ROS was increased in both the 37.5 uM and 50 uM 
samples with EGCG-loaded nanoparticles. 
 
7.4 Concluding summary 
The current aim attempted to demonstrate the feasibility of using the silica nanoparticles 
for therapeutic delivery against acrolein or ROS induction in B35 neuroblastoma cells. 
The current experiments demonstrated a change in therapeutic activity when loaded into 
the nanoparticles, but the change was to the detriment of the cells. Properly identifying 
the "unknown factor" in the nanoparticle-therapeutic interaction would provide insight 
into how the nanoparticles need to be changed to improve delivery. The efficacy was 




































demonstrated a worsening of the ROS and cell death upon loading the EGCG in to the 
nanoparticles. 
 
Various hypothesis were tested to potentially determine how the "unknown factor" 
affects the therapeutically-loaded nanoparticles. Toxicity studies with the loaded 
nanoparticles were not found to affect the cells, but a change in activity was found with 
nanoparticles loaded with EGCG. Using already detrimental concentrations of EGCG, the 
delivery of EGCG using the nanoparticles worsened the effects of the EGCG. The 
increased damage corroborates that the nanoparticles affect the delivery of the 
therapeutic, seemingly increasing the activity, but the precise factors in the interaction are 
unknown and will require further study. 
 
Furthermore, the detriment may stem from the limitation of the cell models at hand. The 
complexity of in vivo problems is obvious, and attempting to study such problems using 
in vitro models is extremely primitive at best. A functioning co-culture model of 
inflammation, such as with the neuronal cells and microglial cells, would have provided 
an additional layer of complexity, but admittedly, the conditions in vivo are still 




8.1 Concluding remarks 
The project described herein had five specific aims to attempt to address how a 
nanomedical system may be used to mitigate the effects of neuronal injury caused by 
oxidative species. 
 
Aim I: Design, synthesize, and characterize hybrid silica nanoparticles.  
The silica nanoparticles were successfully synthesized over the course of the project. Not 
only was the synthesis repeatable with high efficiency, but the nanoparticles remained 
shelf-stable for long periods of time. The synthesis allowed the PEG to be incorporated 
onto the outside of the silica network during the initial formation, eliminating the need 
for a second step to add the stealth polymer. The synthesis also allowed for easy 
fluorescence labeling of the PEG product. Two different PEG products, including from 
different manufacturers, had similar results in size distribution and stability under the 
same synthetic conditions, further supporting the utility of such a synthetic scheme. For 
additional avenues of study, researchers can change the PEG product, most notably the 






Aim II: Evaluate the toxicity of nanoparticles in vitro. 
The silica nanoparticles were found to exhibit low toxicity in the B35 neuroblastoma line, 
but they caused a significant ROS response in C8-B4 glioblastoma cells. When cultured 
together, the ROS response was attenuated by the reduced number of microglial cells. 
Overall, single-cell studies were better indicators for studying the cellular response, as 
many of the studies found artificially high viability counts, but deeper analysis into cell 
number found a change in cellular behavior. The nanoparticle concentrations found to 
cause detrimental effects in both the monoculture and co-culture systems were higher 
than those used for therapeutic delivery, but future improvements in the nanoparticles 
should aim to address toxic responses, such as those seen in the co-culture system, and 
reduce it. 
 
Aim III: Explore natural products catechin and epigallocatechin gallate as potential 
acrolein scavengers. 
Preliminary studies demonstrated that EGCG may be a better candidate for acrolein 
scavenging than hydralazine, but catechin performed similarly to hydralazine. In vitro 
studies with hydrogen peroxide and acrolein demonstrated that hydralazine outperformed 
catechin in preventing cell damage. On the other hand, EGCG prevented acrolein damage 
in lower concentrations than those needed for similar prevention with hydralazine. The 
increased scavenging is attributed to the molar ratios needed for scavenging acrolein. 
Hydralazine can only react with one acrolein molecule, whereas EGCG can react with 
two or three molecules of acrolein. Therefore, studies with EGCG were continued in later 




Aim IV: Explore therapy-nanoparticle interactions in a cell-free system. 
Before moving to an in vitro system, the ability of the nanoparticles to undergo loading 
and interact with hydralazine was studied. Dynamic light scattering studies found that the 
nanoparticles had a concentration-dependent size change when loaded with hydralazine. 
Additionally, using reflective hyperspectral imaging, hydralazine could be found 
interacting with the nanoparticles. Following these experiments, the nanoparticles were 
further studied for their delivery properties in vitro in the project's final aim. 
 
Aim V: Evaluate the efficacy of nanoparticles in vitro. 
The nanoparticles were found to change the delivery of the therapeutics in a cell model 
using iron as a primary injury agent followed by a "secondary injury" of acrolein. The 
change in the delivery was not ideal to save the cells from extensive injury and was found 
to be less effective than the therapeutics alone. The lack of efficacy may be attributed to 
an improper in vitro model. The nanoparticles decidedly require improvements 
(discussed in the next section) and will require numerous studies to understand the 
interaction and delivery of the nanoparticles within tissue culture and how such 
interactions translate to in vivo conditions. 
 
8.2 Future work and recommendations 
These approaches address some of the SCI problems and show promise of using a 
nanomedical approach, but they can be improved. Using nanoparticles to address some of 
the secondary injury problems shows the promise of using a nanomedical approach, but 
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both the delivery systems and therapeutics require improvement. In terms of secondary 
SCI, many of the problems have been identified, but the optimal treatment has yet to be 
determined and methylprednisolone, even with its problems and side effects, is the only 
treatment in clinical use specifically for SCI and MS. Therefore, attempting to mitigate 
its side effects using nanomedicine has a distinct advantage in pushing both the treatment 
of SCI and nanomedicine forward. On the other hand, the need for better treatments is 
self-evident, but those treatments are waylaid by a lack of clinical results. The research 
route of administering an unapproved treatment using nanomedicine is decidedly difficult 
but likely promising in clinical translation. Additionally, scientists have much work in 
convincing government agencies, the pharmaceutical industry, and the public regarding 
the toxicity of nanotechnology in a general sense. Beyond that, they must then be 
convinced that nanomedical systems are beneficial to expand the current research efforts 
and drive improvements in the technology through research. 
 
The project at hand will require fine-tuning of the nanoparticles to improve the 
therapeutic delivery response, which is a major limitation seen in studies up to this point. 
Because of the synthesis technique of silica nanoparticles, commercial companies have 
begun to make them available for researchers. Unfortunately, though, most modifications, 
such as PEGylation, then must be done by the scientist. Changing commercial 
nanoparticles would allow for a systematic study of different PEG polymers for the 
optimum characteristics of delivery and cytotoxicity. In the current study, the synthesis 
relies on the presence of PEG to reduce synthesis steps, but a more sophisticated process 
may be necessary to achieve sustained release and reduced toxicity. New commercial 
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siloxane products are available containing PEG, but researchers are again limited by the 
compounds sold by chemical suppliers unless they want undertake their own synthetic 
methods. One group has established a synthetic protocol where the nanoparticle work-up 
and purification occurs via dialysis at room temperature for about a week using a 
commercial, PEGylated siloxane. They utilize the surfactant used in the traditional 
synthesis, but the surfactant removal occurs in acid at room temperature followed by 
buffer exchange whereas the traditional route involved refluxing in acidic solvent, solvent 
removal, and suspension in the appropriate buffer.[167] By keeping the nanoparticles in 
solution, it reduces the aggregation seen in many solvent-removal schemes. 
 
With improved delivery, more positive results may be obtained from EGCG or other 
natural products. Their limited use is well known already, and an improvement in 
delivery using nanomedicine would likely push the efficacy of natural products much 
further. Other directions with EGCG include conjugating the compound to the 
nanoparticle, which could also increase its absorption. Various synthetic work has been 
done to add moieties to EGCG. Based on its molecular structure, many click chemistry 
reactions would likely be useful, as well. 
 
Another limitation of the study involved the lack of a valid cellular model for spinal cord 
injury. Further work should explore and determine a model that exhibits similar 
characteristics in vitro. Most models of spinal cord injury rely on animal studies, and the 
literature shows a wide array of in vitro models only scarcely related to what happens in 
vivo. Part of the secondary biochemical cascade includes inflammation; therefore, a co-
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culture model using both neurons and supporting cells would be a closer, albeit primitive, 
model to the problems observed in vivo. By studying the inflammatory response and 
biological responses in the in vitro model, one may be able to improve the nanoparticles 
and therapeutics even further. For instance, aldehyde-reactive probes and antibodies for 
acrolein-modified proteins could highlight the type of damage being induced in the co-
culture model. Upon classifying the damage, the nanoparticles could be specifically 
tailored to mitigate the immune response or to fight the oxidative stress. The nanomedical 
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